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THE CAPTIVE LAB RAT: HUMAN MEDICAL 
EXPERIMENTATION IN THE CARCERAL STATE 
LAURA I APPLEMAN* 
Abstract: Human medical experimentation upon captive, vulnerable subjects is 
not a relic of our American past. It is part of our present. The extensive history of 
medical experimentation on the disabled, the poor, the mentally ill, and the incar-
cerated has been little explored. Its continuance has been even less discussed, es-
pecially in the legal literature. The standard narrative of human medical experi-
mentation ends abruptly in the 1970s, with the uncovering of the Tuskegee syphi-
lis study. My research shows, however, that this narrative is incorrect and incom-
plete. The practice of experimenting on the captive and vulnerable persists. Our 
current approach to human medical experimentation disregards informed consent 
and privacy, allowing the pharmaceutical and medical industries to play an out-
sized role in shaping clinical research. The confusing amalgam of laws, rules, 
and codes loosely governing such research almost entirely fails to regulate or 
prevent patient mistreatment and abuse. Acquiring a true understanding of our 
system of mass incarceration requires us to unearth the hidden contours of our 
current experiments on the poor, the disabled, and the confined, and calls for a 
wholesale revision of the flawed legal and medical regime overseeing human 
medical experimentation. 
INTRODUCTION 
In 1949, the Quaker Oats Company collaborated with the Massachusetts 
Institute of Technology (MIT) and the Atomic Energy Commission (AEC) to 
lace oatmeal with radioactive tracers and feed it to seventy-four boys, aged ten 
to seventeen, who resided in an institution for the developmentally disabled.1 
The only consent obtained was from the institution’s director. The experiment-
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versity. J.D., Yale University; B.A., M.A., University of Pennsylvania. Thanks to David Friedman, 
Carissa Hessick, Elizabeth Kaplan, Aaron Simowitz, Chris Slobogin, Robin Wilson, Mindy Zeitzer, 
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 1 Lorraine Boissoneault, A Spoonful of Sugar Helps the Radioactive Oatmeal Go Down, SMITHSON-
IAN MAG. (Mar. 8, 2017), https://www.smithsonianmag.com/history/spoonful-sugar-helps-radioactive-
oatmeal-go-down-180962424/ [https://perma.cc/K8EG-VHPX]. 
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ers lured the boys into participation by telling them that they would be joining 
a special “Science Club.”2 
Quaker was in the midst of a pitched battle with Cream of Wheat over hot 
breakfast cereal market share, and was concerned that their oats might prevent 
iron absorption (unlike farina).3 They slipped radioactive particles into the 
breakfasts of unknowing children as an experiment to trace how iron was in-
ternally absorbed.4 One of Quaker’s advertisements from the era boldly pro-
claimed “Eat Quaker Oats for Energy!”5 
This experimental research using captive6 human subjects—one of many 
since the beginning of the American carceral nation—is not an outlier story. In 
fact, this experiment reflects our broader approach towards those whom we 
incarcerate, institutionalize, or involuntarily confine.7 The extensive history of 
medical experimentation on the disabled, the poor, the chronically ill, and the 
imprisoned is deeply shocking, but has been little explored. The gross mis-
treatment of the unknowing, non-consenting, and physically captive—the “de-
valued experiences of people of low social status”8—presents a disturbing sto-
ry that must be told if we are to understand and reckon with the future of those 
we confine. 
Despite the confusing amalgam of rules and regulations that currently 
loosely oversees human medical experimentation, the typical history of human 
subject research does not discuss the modern era.9 The standard narrative con-
cludes that by the mid-1970s, most medical research on captive populations 
                                                                                                                           
 2 Id. 
 3 Id. 
 4 Id. 
 5 Id. 
 6 “Captive” includes the incarcerated, institutionalized, or hospitalized, wards of the state, and 
long-term care residents, among others. 
 7 See generally Laura I Appleman, Deviancy, Dependency, and Disability: The Forgotten History 
of Eugenics and Mass Incarceration, 68 DUKE L.J. 417 (2018) (explaining how the incarceration of 
the disabled is a significant, yet often forgotten, part of the United States’ history of imprisonment). 
 8 ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT HOLMESBURG PRISON, A 
TRUE STORY OF ABUSE AND EXPLOITATION IN THE NAME OF MEDICAL SCIENCE, at xix (1998). 
 9 Cf. Michele Goodwin, Vulnerable Subjects: Why Does Informed Consent Matter?, 44 J.L. MED. 
& ETHICS 371, 376 (2016) (discussing instances in which informed consent to medical experimenta-
tion failed in the 1960s); Jay Katz, Human Sacrifice and Human Experimentation: Reflections at Nu-
remberg, 22 YALE J. INT’L L. 401, 407 (1997) (arguing for stricter regulation of informed consent by 
showcasing examples of medical experimentation during World War II); Matt Lamkin & Carl Elliott, 
Involuntarily Committed Patients as Prisoners, 51 U. RICH. L. REV. 1041, 1042 (2017) (arguing 
against the use of involuntarily committed patients in human medical experiments); Keramet Reiter, 
Note, Experimentation on Prisoners: Persistent Dilemmas in Rights and Regulations, 97 CALIF. L. 
REV. 501, 510 (2009) (discussing human medical experimentation and arguing for loosened re-
strictions). 
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ended.10 My research shows, however, that this history is incorrect and incom-
plete. As I detail, the practice of experimenting on the captive and vulnerable 
persists, whether inmates, the mentally ill, the institutionalized, or wards of the 
state. This is not a story that belongs to history. These practices endure today. 
The full social ramifications of human medical experimentation on the 
captive and vulnerable have been little explored. This part of our past is well 
documented in medical journals, occasional media stories, and government 
reports, but is otherwise little mentioned in the legal literature, despite the con-
tinuing practice. Acquiring a true understanding of our system of mass incar-
ceration requires us to unearth this history of experimenting on poor, disabled, 
and confined citizens, as well as sharply scrutinize today’s continuing human 
medical experiments in restrictive settings such as correctional facilities, foster 
care, psychiatric institutions, and hospitals. 
Part I of this Article discusses America’s history of experiments on the 
captive patient, whether enslaved, imprisoned, sequestered in asylums, institu-
tionalized, or abandoned to the state.11 Part II reveals how our practice of ex-
perimenting on the incarcerated has continued through the late twentieth and 
early twenty-first century, despite the various federal and state laws ostensibly 
regulating such practices.12 Part III shows our troubling current state of captive 
medical experimentation, focusing on the evisceration of informed consent and 
privacy in such cases, and closely examining the role of the medical industry 
in furthering such research.13 In Part IV, I offer means of confronting and ad-
dressing the continuing practices of human medical experimentations on the 
vulnerable and captive.14 I argue for maintaining or tightening current re-
strictions and suggest that we should make use of future possible technological 
solutions, but warn that the root problems remain. I conclude by calling for a 
wholesale revision of the flawed oversight of human medical experimentation 
to best end the abuses that still endure. 
I. A HISTORY OF CAPTIVITY AND EXPERIMENTATION 
America’s long history of performing medical research and experiments 
on the captive and vulnerable is just beginning to enter public consciousness.15 
                                                                                                                           
 10 See HORNBLUM, supra note 8, at xv (asserting that most medical experimentation on institu-
tionalized persons ended in the 1970s because regulation on such research was greatly increased). 
 11 See infra notes 15–193 and accompanying text. 
 12 See infra notes 194–423 and accompanying text. 
 13 See infra notes 424–520 and accompanying text. 
 14 See infra notes 521–599 and accompanying text. 
 15 See Esther Choo, The James Marion Sims Problem: How Doctors Can Avoid Whitewashing 
Medicine’s Racist History, NBC NEWS (June 7, 2018), https://www.nbcnews.com/think/opinion/
james-marion-sims-problem-how-doctors-can-avoid-whitewashing-medicine-ncna880816 [https://
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In May 2018, New York City’s Central Park removed a statue of Dr. Marion 
Sims, the celebrated “father” of gynecology, after acknowledging his legacy of 
testing of gynecological surgical techniques on slaves without anesthesia.16 
Instead of destroying the statute outright, the city moved it elsewhere, to better 
“remember darker moments in history, if not elevate them.”17 
Reckoning with the practice of eugenics in medical history has taken 
equally long within the law. An understanding of our past experience with eu-
genics and incarceration is just beginning to emerge. Likewise, the twined his-
tories of medical research and experimentation on captive, vulnerable Ameri-
cans have not truly permeated our standard understanding of the modern car-
ceral state. This account seeks to fill in the missing narrative, with an eye to-
ward moving to quick and necessary reform. 
A. Asylums and Institutions 
Around the establishment of the American asylum, human medical exper-
iments, which were routinely conducted on the involuntarily institutionalized, 
began to flourish. The proliferation of various institutions, including orphanag-
es, reformatories, foundling homes, asylums, leper colonies, and hospitals, of-
fered many subjects for medical experimentation in controlled test environ-
ments.18 
During the late nineteenth century, pediatric asylums in particular drew 
many doctors looking for tractable subjects.19 In 1883, for example, Dr. 
George L. Fitch, the resident physician to the Hawaiian leper colony,20 injected 
what he believed was the syphilis “virus” into six girls under the age of 
twelve.21 Fitch repeated his experiments on more leprosy patients and ultimate-
ly published his findings in a medical journal.22 Not long after, in 1895, Dr. 
Henry Heiman successfully exposed and cultivated gonorrhea in a disabled, 
epileptic four-year old boy and a developmentally disabled sixteen-year old 
                                                                                                                           
perma.cc/Y5K4-FH3S] (noting that New York City removed the statute of James Sims, who had used 
slaves to test new surgical procedures). 
 16 See id. 
 17 Id. 
 18 Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experimentation, in 
CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 3, 6 (Michael A. Grodin & Leonard 
H. Glantz eds., 1994). 
 19 Id. 
 20 SUSAN E. LEDERER, SUBJECTED TO SCIENCE: HUMAN EXPERIMENTATION IN AMERICA BE-
FORE THE SECOND WORLD WAR 61 (1995). 
 21 Lederer & Grodin, supra note 18, at 7. 
 22 LEDERER, supra note 20, at 61. 
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boy in order to study the disease’s contagious nature.23 He obtained no consent 
from the children or any of their parents or guardians.24 
Mental asylums also became a favored place to conduct medical experi-
ments. In 1897, Dr. Henry Berkley, a Johns Hopkins neuropathy associate, 
tested various levels of thyroid extract on eight severely mentally ill patients.25 
Berkley administered the extract in increasing doses, causing weight loss, cir-
culation disturbances, digestive upset, irritability, and sometimes “frenzy” or 
great “mental excitement” in the inmates.26 One patient suffered severe mental 
and motor distress for seven weeks, with the symptoms continuing until her 
death.27 The minor payoff derived from this experiment? The discovery that 
even pure thyroid extract could harm a patient.28 The suffering of the patients 
merited little to no attention.29 
Dr. Carl Janson famously quipped that he experimented on foundlings 
and orphans because they were “cheaper than animals.”30 The lack of reliable 
animal subjects at the turn of the twentieth century did lead to the use of insti-
tutionalized adults and children as “animals of necessity” for experimental 
testing of the bacterial causes of disease.31 Deliberate attempts to infect the 
institutionalized included exposure to “cancer, leprosy, syphilis, gonorrhea, 
tuberculosis, and yellow fever . . . .”32 
Doctors also used the institutionalized as experimental subjects for vac-
cines and diagnostic tests, only sometimes with incidental beneficial effect.33 
In 1887, Dr. Joseph Stickler, in an attempt to find a scarlet fever vaccine, “in-
oculated” himself and several children with equine foot and mouth disease; 
this resulted in little contagion, but also zero vaccination effect.34 In 1912, Dr. 
Carl von Ruck tested his live tuberculosis vaccine on 262 North Carolina or-
phans, despite evidence suggesting that recipients of his tuberculosis “vaccine” 
succumbed to tuberculosis more frequently than the unvaccinated.35 
The first two decades of the twentieth century saw a grim expansion of 
vaccine testing on institutionalized children. Orphanages and children’s hospi-
tals became staging grounds for attempts to develop measles, mumps, chicken 
                                                                                                                           
 23 See Lederer & Grodin, supra note 18, at 7. 
 24 See id. 
 25 LEDERER, supra note 20, at 50–51. 
 26 See id. 
 27 Id. at 61–62. 
 28 Id. at 62. 
 29 See id. (noting that the experimenter’s conclusions did not discuss patient pain and suffering). 
 30 Lederer & Grodin, supra note 18, at 7. 
 31 Id. 
 32 Id. 
 33 Id. at 6. 
 34 Id. at 8. 
 35 Id. 
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pox, and whooping cough vaccines.36 Consent was rarely obtained, even where 
parents were available to ask, and the vaccines usually failed, often with nega-
tive consequences for the children.37 
The U.S. Army also used asylum inhabitants to study common diseases. 
In order to better understand the spread of influenza in troops, Drs. Jonas Salk 
and Thomas Francis sprayed wild flu virus into the nasal passages of “large 
numbers” of mental institution inmates in 1941, almost all of whom developed 
the disease as a result.38 
In a second experiment, to test a newly created vaccine for American 
troops, Drs. Salk and Francis vaccinated half of the impoverished inhabitants 
of two state hospitals, purposely exposing all the patients to influenza.39 It is 
notable that even in a relatively recent report, an Army Medical History report 
recounted these experiments in admiration as “remarkable and daring,”40 with 
only an offhand admission that this would be found “highly unethical” today.41 
Researchers also found easy subjects in developmentally disabled chil-
dren, because their institutions (and occasionally, their parents) readily gave 
permission for medical experimentation. At New York’s Willowbrook School, 
which housed children who were severely developmentally disabled, doctors 
tested a series of hepatitis vaccines from 1956 to 1970.42 The research involved 
purposefully infecting sixty healthy children with hepatitis to aid in vaccine 
development.43 Most developed hepatitis and suffered from symptoms includ-
ing “fever, nausea, vomiting, intolerance to food, jaundice (a yellowing of the 
skin and eyes), and liver damage.”44 
Scientists justified the deliberate infection by arguing that most Willow-
brook residents caught hepatitis within their first year anyway, given the insti-
tution’s unsanitary conditions, overcrowding, close quarters, and rapid spread 
of infectious disease.45 As long as the results would ultimately benefit both the 
public and Willowbrook patients, the reasoning went, the intentional infection 
of disabled children and the suffering caused did not matter.46 
                                                                                                                           
 36 Id. 
 37 Id. 
 38 Gordon Meiklejohn, History of the Commission on Influenza, in THE HISTORIES OF THE COM-
MISSIONS 143–44, 154 (Theodore E. Woodward ed., 1994). 
 39 Id. at 154. 
 40 Id. at 143. 
 41 Id. at 144. 
 42 FREDERICK ADOLF PAOLA ET AL., MEDICAL ETHICS AND HUMANITIES 185–86 (2010). 
 43 See PAUL A. OFFIT, THE CUTTER INCIDENT: HOW AMERICA’S FIRST POLIO VACCINE LED TO 
THE GROWING VACCINE CRISIS 37 (2007); PAOLA ET AL., supra note 42, at 185. 
 44 OFFIT, supra note 43, at 37. 
 45 PAOLA ET AL., supra note 42, at 185–86. 
 46 See Goodwin, supra note 9, at 376 (noting that researchers were convinced that these experi-
ments would ultimately benefit all parties involved). 
8 Boston College Law Review [Vol. 61:1 
In one particular case, the children’s parents consented to the experiment, 
but only because the doctor made their children’s enrollment into the asylum 
conditional upon consent to hepatitis infection.47 Of course, these misrepresen-
tations to the parents, along with the duress in the inducement, rendered such 
agreements invalid.48 Similar federally funded experiments exposed Connecti-
cut mental asylum patients to hepatitis, in hopes of separating out the different 
strains of the virus.49 
As mentioned previously, the developmentally disabled, “troubled,” and 
destitute boys who lived at the Fernald School in Waltham, Massachusetts also 
served as unknowing subjects of medical experiments. In the Fernald experi-
ments, the children received doses of radioactive iron or calcium to determine 
whether phytates were blocking absorption of essential minerals.50 With assis-
tance from the federal AEC, MIT’s Radioactivity Center created the Fernald 
“Science Club” to induce the boys into participating in the experiments, where 
radioactive isotopes were mixed in to either milk or oatmeal to be consumed 
daily.51 This particular experiment involved seventy-four Fernald boys, stretch-
ing from 1946 to 1953.52 
Researchers and doctors favored the Fernald School as a place to imple-
ment a variety of experimental projects, given its “ideal population” of captive 
children a mere twenty or so miles away from the scientific research communi-
ty in Boston.53 Indeed, such was the diversity and sheer variety of ailments at 
Fernald that many researchers began to refer to the school as the “zoo.”54 
As a consequence, Fernald hosted numerous scientific studies on its 
wards for almost sixty years, including vaccine tests for childhood diseases 
such as whooping cough, measles, and diphtheria.55 New nasal discharge drugs 
were tested on children with Down Syndrome.56 Scientists tested hormones 
and performed biopsies on prepubescent children.57 The radioactivity study, 
                                                                                                                           
 47 See DAVID J. ROTHMAN & SHEILA M. ROTHMAN, THE WILLOWBROOK WARS: BRINGING THE 
MENTALLY DISABLED INTO THE COMMUNITY 258 (1984). 
 48 See PAOLA ET AL., supra note 42, at 185 (noting that such agreements have been questioned 
and characterized as “inadequate consent” due to duress at the time consent was given). 
 49 Mike Stobbe, Past Medical Testing on Humans Revealed, WASH. POST (Feb. 27, 2011), http://
www.washingtonpost.com/wp-dyn/content/article/2011/02/27/AR2011022700988.html [https://perma.
cc/2P5M-ZAW4]. 
 50 EILEEN WELSOME, THE PLUTONIUM FILES: AMERICA’S SECRET MEDICAL EXPERIMENTS IN 
THE COLD WAR 231 (1999). Phytates are “chemicals found in cereals that can combine with iron and 
calcium to form insoluble compounds.” Id. 
 51 Id. at 231, 233–34. 
 52 Id. at 231. 
 53 Id. at 232–33. 
 54 Id. at 233. 
 55 Id. 
 56 Id. 
 57 Id. 
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however, was the longest and most far-reaching of all the medical experi-
ments.58 
The AEC’s radioisotope distribution system in Oak Ridge, Tennessee59 
provided the radioactive calcium60 to assist the MIT scientists in their experi-
ment. Although the AEC Subcommittee on Human Application generally dis-
couraged testing of radioactive substances on “normal children,” it permitted 
larger doses of radioactive material for developmentally disabled children.61 
The AEC approved the trace radioactivity study with the Fernald boys, as well 
as a 1961 Harvard Medical School experiment that “administered small 
amounts of radioactive iodine to seventy children at the Wrentham State 
School,” in order to test a preventative countermeasure for potential nuclear 
fallout.62 The AEC also approved an experiment to inject a much larger 
amount of radioactive calcium into a child suffering from Hurler-Hunter syn-
drome.63 
For the innocent Fernald School boys participating in the MIT-created 
“Science Club,” the multiple X-rays, blood tests, and collection of their urine 
and stool samples seemed a tolerable price to pay for admittance.64 The boys 
thought that the tests were for either the 4-H club or for a vitamin study, and had 
no idea they were consuming radioactive isotopes with their breakfast.65 The 
scientists also gave the boys’ parents misleading information. For example, the 
scientists sent letters explaining that the nutritional studies being done would 
benefit the boys, as the children received a “special diet ‘rich’ in various cereals, 
iron, and vitamins.”66 The letters never mentioned radioactivity.67 When the sci-
entists did not receive a response, they assumed that the parents approved.68 
                                                                                                                           
 58 See id. at 231 (noting that the radioactivity experiments were conducted on seventy-four chil-
dren and went on for seven years). 
 59 The Isotopes Division of the Research Division at Oak Ridge was originally part of the Man-
hattan Project. Post-war, the Manhattan Project began distributing radioactive isotopes to various 
medical researchers and scientists for further experimentation. See ADVISORY COMM. ON HUMAN 
RADIATION EXPERIMENTS, U.S. DEP’T OF ENERGY, FINAL REPORT 285 (1995). 
 60 See WELSOME, supra note 50, at 233. 
 61 See id. 
 62 ADVISORY COMM. ON HUMAN RADIATION EXPERIMENTS, supra note 59, at 320. 
 63 See WELSOME, supra note 50, at 234 (noting that the AEC granted the Harvard Medical School 
permission to inject a child with fifty microcuries of radioactive calcium and that the associated scien-
tific paper indicated that the researchers actually injected the individual with eighty microcuries). 
Hurler-Hunter syndrome is a “metabolic disorder that causes severe skeletal abnormalities, dwarfism,” 
and developmental disability. Id. 
 64 Id. at 235. 
 65 Id. 
 66 ADVISORY COMM. ON HUMAN RADIATION EXPERIMENTS, supra note 59, at 342. 
 67 See WELSOME, supra note 50, at 235. 
 68 ADVISORY COMM. ON HUMAN RADIATION EXPERIMENTS, supra note 59, at 292. 
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This type of human medical experimentation using radioactive materials 
was not confined to children. For years, the AEC permitted experiments using 
radioactive substances on institutionalized, developmentally disabled adults.69 
Between 1931 and 1933, for example, researchers injected mentally ill patients 
with 70 to 450 micrograms of radium-226 as part of an experimental therapy 
for mental disorders.70 The researchers hoped to construct a valid retention 
curve for radium in humans over several decades.71 The radium’s side effects 
were of little concern to the scientists.72 
Medical experimentation on institutionalized children included the physi-
cally disabled as well as the developmentally disabled. For five years, between 
1955 and 1960, a Californian hospital and foundling home for physically and 
developmentally disabled children, Sonoma State Hospital, performed a varie-
ty of experiments on its patients.73 The experiments conducted on the children, 
without their or their parents’ consent, allegedly included radiation tests, 
pneumoencelphalograms, a painful procedure by which air is injected into the 
brain and followed by a number of X-rays, and unauthorized dissection of the 
children’s brains after death.74 
Despite these myriad violations of children’s bodily autonomy, no current 
federal regulations specifically protect institutionalized children from discrim-
inatory or unethical treatment in research involving human subjects.75 Alt-
hough general regulations regarding the use of children in research apply,76 
institutionalized children do not get any special or extra protection. This is just 
one example of how the law has failed to fully and comprehensively protect 
vulnerable, captive populations from human experiments. 
B. Orphanages, Foundling Homes, and Children’s Hospitals 
Institutions for children began to multiply in the 1830s.77 Both foundling 
homes and children’s hospitals were created to house neglected, deserted, ill, 
                                                                                                                           
 69 See List of Experiments, DOE OPENNESS: HUMAN RADIATION EXPERIMENTS, https://ehss.
energy.gov/OHRE/roadmap/experiments/0491doca.html#0491_Plutonium [https://perma.cc/AS8K-
6V5J] (listing the various experiments). 
 70 See id. 
 71 See id. 
 72 See id. (noting the injection of radium-226 with little tracking of the patients’ long-term health). 
 73 See Rebecca Leung, A Dark Chapter in Medical History, CBS NEWS (Feb. 9, 2005), https://
www.cbsnews.com/news/a-dark-chapter-in-medical-history-09-02-2005/ [https://perma.cc/FN8P-
GQ9Q]. 
 74 See id. 
 75 See ADVISORY COMM. ON HUMAN RADIATION EXPERIMENTS, supra note 59, at 323. 
 76 See 45 C.F.R. §§ 46.403–.407 (2018). 
 77 See Susan E. Lederer, Orphans as Guinea Pigs: American Children and Medical Experiment-
ers, 1890–1930, in IN THE NAME OF THE CHILD: HEALTH AND WELFARE 1880–1940, at 96, 98 (Roger 
Cooter ed., 1992). 
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and destitute children as well as provide moral and medical care.78 Because 
charity hospital patients in essence existed to provide training and clinical ma-
terial for doctors, these children’s institutions provided experimentation oppor-
tunities for elite physicians.79 Accordingly, the amount of pediatric medical 
experimentation that occurred is far greater than commonly appreciated.80 In 
an era where healthy institutionalized children were sent out to work on farms 
in New York and the Midwest,81 their frailer brethren were made to earn their 
keep by being subjects in various medical research projects. 
Asylums and orphanages were popular sites to conduct medical experi-
ments because consent issues rarely, if ever, surfaced.82 Getting permission 
from any remaining parents or guardians was not considered an issue.83 Dr. 
Alfred Hess’s research at the Hebrew Orphan Asylum in the 1920s on the die-
tary factors of rickets84 and scurvy85 is emblematic.86 Dr. Hess withheld orange 
juice from infants and young children until they developed the painful hemor-
rhages typical of scurvy, and he fed children a similarly restricted diet in an 
attempt to induce the bone-weakening symptoms of rickets.87 Some of the 
children never fully recovered from the effects of these diseases.88 
Vaccine testing also took place in orphanages because children often had 
not been exposed to infectious diseases.89 In 1895, Drs. Walter Reed and 
George Sternberg tested the immunity granted by smallpox vaccines at or-
phanages in Brooklyn; the most common way to test immunity was to inject 
the children with active smallpox virus, which could kill or deform the pa-
tients.90 
                                                                                                                           
 78 See id. at 96. 
 79 See id. at 99–100. 
 80 See id. at 97. 
 81 See id. at 99. In 1854, New York’s Children’s Aid Society began sending healthy orphans to 
farms across the country. Id. The asylums, orphanages, and pediatric hospitals were created to house 
the younger and less hardy candidates. Id. 
 82 LEDERER, supra note 20, at 15–16. 
 83 Id. at 16. 
 84 Rickets is the deterioration of bones in children, often resulting from a severe vitamin D deficien-
cy. Rickets can cause skeletal deformities such as bowed legs, knock knees, thickened ankles and wrists, 
and breastbone projections. See Rickets Overview, MAYO CLINIC, https://www.mayoclinic.org/diseases-
conditions/rickets/symptoms-causes/syc-20351943 [https://perma.cc/CGD7-QPKM]. 
 85 Scurvy is a vitamin C deficiency that can lead to anemia, debility, exhaustion, spontaneous 
bleeding, pain in the limbs and especially the legs, swelling in some parts of the body, and sometimes 
ulceration of the gums and loss of teeth. See Peter Crosta, Everything You Need to Know About Scur-
vy, MED. NEWS TODAY (Dec. 5, 2017), https://www.medicalnewstoday.com/articles/155758.php 
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Researchers also repeatedly tested tuberculosis vaccines on orphans. In 
1913, 262 children in a North Carolina orphanage were used to test a vaccine 
against the disease.91 The U.S. Senate eventually commissioned an investiga-
tion that called into question the vaccine’s safety and raised the possibility that 
the vaccine actually made the children more susceptible to tuberculosis.92 
Analogous research and tests were carried out on newborn infants to test 
gastric hunger.93 Similarly, children at St. Vincent’s Hospital were likewise 
infected with a contagious skin disease (molluscum contagiosum)94 and 
whooping cough.95 Typically viewed as expendable and unimportant, poor, 
abandoned, and vulnerable children have historically borne the brunt of medi-
cal research’s expanding scope. 
C. Hospitals and Invalid Homes for the Poor 
As hospitals expanded during the late nineteenth century, they served as 
yet another setting to perform human medical experiments, with or without 
consent. Unlike the modern hospital, the late nineteenth century and early-to-
mid-twentieth century hospital was “less an institution for healing than a phy-
sician-centered venue for learning, training, and experimental approaches.”96 
Unregulated research on impoverished hospital patients continued, with 
little oversight, well into the twentieth century. Between 1943 and 1944, re-
searchers at the Manhattan Engineer District’s Metallurgical Laboratory tested 
the changes in blood after total body irradiation (TBI)97 at the University of 
Chicago’s Billings Hospital.98 Eleven patients were subjected to X-ray radia-
tion, eight with incurable neoplasms, and three with generalized, chronic ill-
ness.99 There is no record of any consent.100 As a result of the experiment, most 
of the patients’ white blood cells were severely diminished.101 
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Many hospital-based radiation experiments in the early to mid-twentieth 
century enjoyed sponsorship from the U.S. government. During and after 
World War II, officers running the Manhattan Project decided to experimental-
ly inject plutonium into unwitting hospital patients.102 The government wished 
to “clarify the relative toxicity of radium and plutonium and help establish tol-
erance levels for workers.”103 Four separate research institutions conducted 
experiments in 1946 and 1947, in which the researchers injected terminally ill 
patients with radioactive plutonium to determine how it would affect the 
body.104 None of the treatments were found to be therapeutic, and significant 
pain resulted for the patients.105 
The pace of experimentation on cancer patients with radioactive materials 
increased after World War II. In 1947, the Argonne Laboratory in Chicago in-
travenously injected twelve hospital patients with radioactive arsenic-76, to 
“study the uptake, retention, distribution, and excretion of arsenic.”106 The ra-
dioactive arsenic-76 failed to cure the cancers of the various subjects.107 
In the early 1950s, former Nazi physiologist Herbert Gerstner subjected 
263 cancer patients to TBI at M.D. Anderson Hospital for Cancer Research in 
Houston, Texas.108 All of these patients had radioresistant carcinomas, for 
which “cure by conventional means was regarded as completely hopeless.”109 
The TBI completely destroyed the patients’ bone marrow, leading to fatal ane-
mia and rapid death.110 Although the patients signed a rudimentary release 
form, the release did not inform them of the risks and benefits.111 Many of the 
patients were indigent members of minority groups, although no precise rec-
ords were kept.112 
In a similar vein, Dr. Chester Southam of Sloan Kettering spent 1963 to 
1964 injecting live cancer cells into twenty-two highly debilitated patients 
(who did not have cancer)113 in long-term care at the Jewish Chronic Disease 
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Hospital.114 All twenty-two were frail and elderly, many mentally incompetent, 
and several were survivors of the Holocaust who spoke primarily Yiddish.115 
Despite the relatively recent establishment of the Nuremberg Code116 and the 
parallels to Nazi experimentation in concentration camps, the experiment was 
performed without any review board approval or interventions on behalf of the 
patients.117 
Although the patients had theoretically consented to the experiment, they 
were not aware of the cancer cell injection.118 Instead, Dr. Southam told the 
patients they were being injected with human cells grown in test tubes, cells 
that would create a temporary nodule.119 While technically correct, this was 
not the entire truth. Although the experiment stopped in 1964 due to a public 
outcry, Dr. Southam ultimately became the president of the American Associa-
tion of Cancer Research in 1968.120 
This tolerance for experimentation on unknowing cancer patients contin-
ued through the early 1970s. In Cincinnati, radiologist Dr. Eugene Saenger 
used experimental, high-dose TBI on approximately ninety cancer patients 
with localized, radio-resistant cancers.121 The TBI used by Dr. Saenger con-
sisted of magnavolt X-rays, cobalt-60, or cesium-137, in amounts equal to ap-
proximately 15,000 chest X-rays to the entire body.122 Although by the 1940s, 
scientists knew that TBI was only effective against certain radiosensitive can-
cers, such as leukemia and lymphoma, Saenger still obtained funding from the 
Pentagon.123 
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None of this information was shared with the Cincinnati cancer patients, 
who were told only that TBI was the appropriate treatment.124 The majority of 
the cancer patients were poor or working-class, and about sixty percent were 
African-American.125 Saenger’s research partner, Clarence Lushbaugh, ex-
plained that they chose “slum patients” because “these persons don’t have any 
money and they’re black and they’re poorly washed.”126 
The TBI resulted in death for one out of four patients, who perished within 
the month, “suffering anemia, vomiting, and crashing white blood cell counts.”127 
The results were so drastic that even other doctors criticized Saenger’s experi-
ments, calling them “too dangerous” and “terrible human studies.”128 Whether 
there was written signed consent is disputed, but highly unlikely.129 The exper-
iment ended in 1972 after the Department of Defense cut the funding for the 
nearly million-dollar research.130 
Despite the controversy over the TBI experiments, Saenger taught at the 
University of Cincinnati Medical School until his death.131 The Radiological 
Society of North America gave him its highest honor, a Gold Medal, for his 
work in radiology, including his TBI experiments.132 Saenger never suffered 
any serious repercussions from the experiments.133 
Only a tiny, out-of-the-way plaque at the University of Cincinnati memo-
rializes the seventy patients who died from the experiments, required as part of 
the settlement made by the university with the patient survivors and their fami-
lies.134 This small, neglected plaque exemplifies the way that we remember the 
history of these experiments on poor, often minority individuals institutional-
ized in hospitals for necessary treatments. Little attention was paid then to their 
rights or their suffering, and little more attention is paid now. 
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D. Prisoners 
The number, size, and frequency of medical experiments that have been 
carried out on incarcerated citizens are too vast to fully recount. Instead, this 
Section explores the most infamous and troubling of these studies, leading to 
inescapable conclusions when looking at them in toto. 
Prisoners have often been viewed as the perfect experimental test sub-
jects, given their captivity, their limited freedoms, and the sheer number of po-
tential bodies in one place. As such, inmates were subjected to many inhumane 
medical experiments throughout the twentieth century. In the 1920s, for exam-
ple, inmates at San Quentin penitentiary were subjected to experiments in tes-
ticular transplantation, to determine whether “lost potency of aged and ill men 
could be reinvigorated.”135 Dr. L.L. Stanley transplanted testes from recently 
executed prisoners into eleven healthy prisoners.136 The San Quentin doctors 
also transplanted ram testes into twenty-three inmates who suffered from vari-
ous medical issues.137 Over the course of three years, 500 prisoners had tes-
ticular transplants.138 Needless to say, these transplants were unsuccessful. 
World War II sparked a tremendous boom in medical experimentation on 
the incarcerated. With soldiers dying in Europe and the South Pacific, the de-
mand for human research material increased.139 In 1942, a variety of risky 
medical experiments were practiced on state prisoners, including injections of 
cattle blood as a potential new source of plasma (critical to wounded soldiers), 
atropine140 studies, and research involving “sleeping sickness, sandfly fever, 
and dengue fever.”141 Inmates in federal prisons took part in an equally wide 
range of medical experiments, including exposure to sexually transmitted dis-
eases such as gonorrhea, recurring sicknesses like malaria,142 and induction of 
gas gangrene.143 
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The post-war focus on prison experimentation can also be linked to the 
immense growth in the pharmaceutical and health care industry.144 A vast wave 
of prisoner experiments began, with funding coming from both the government 
and various for-profit corporations.145 After World War II, the United States 
stood alone in permitting experimentation on prisoners. Europe and the South 
Pacific, having been far closer to both medical and wartime atrocities, inter-
preted the Nuremberg Code to ban medical experimentation on prisoners en-
tirely.146 
In contrast, American medical researchers, perhaps feeling unburdened by 
the legacy of wartime history, performed multiple medical experiments on the 
incarcerated.147 Indeed, researchers used prisoners as subjects in a wide variety 
of studies, ranging from cancer research to experimental testing of cosmet-
ics.148 Accordingly, “what had once been a small, underfunded, unsophisticated 
cottage industry” became “a well-financed, broad clinical research program” 
testing new and innovative medical treatments.149 The post-war expansion of 
experimentation on prisoners was unprecedented and virtually unregulated.150 
So encouraged, scientists in the late 1940s studied the transmission of 
dangerous intestinal viruses by having New York State Vocational Institution 
prisoners swallow unfiltered stool suspension.151 This was to test the viral con-
tagion.152 It is unknown whether these prisoners were ever compensated.153 
Often prominent universities, hospitals, scientists, and prisons collaborat-
ed to perform these medical experiments on the incarcerated. In 1953, Univer-
sity of Chicago and the Argonne Cancer Research Hospital conducted experi-
ments on Illinois State Penitentiary inmates to “determine the hemolytic defect 
that develops during primaquine administration.”154 Blood-containing chromi-
um-51 was injected into the prisoners, followed by an injection of prima-
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quine.155 Those prisoners who were sensitive to primaquine developed severe 
anemia, including rapid heartbeat, fatigue, shortness of breath, chest pain, and 
cramps.156 
By the 1960s, over half the states permitted prisoners to be used as “med-
ical guinea pigs.”157 Human experimentation quickly followed. Drs. Carl Hel-
ler and Alvin Paulsen, with the explicit permission of the AEC, performed a 
series of radiation experiments on Washington and Oregon prisoners.158 The 
two doctors irradiated prisoner testicles with 8 to 600 rads of radiation, as well 
as injections with carbon-14, a radioactive tracer.159 Each dose of radiation was 
stronger than twenty modern diagnostic X-rays would provide today.160 
The Washington and Oregon experiments continued until 1971, using 131 
inmates as experimental subjects.161 Additionally, researchers performed nu-
merous biopsies of the inmates’ reproductive organs, vasectomizing them 
when the studies were over.162 “Compensation” for these procedures was five 
dollars a month during the program, ten to twenty-five dollars for each biopsy, 
and one hundred dollars post-vasectomy.163 In contrast, Paulsen received 
$505,000 from the AEC for his work.164 
After each irradiation session, rashes, peeling, and blistering on inmates’ 
scrotums soon followed.165 The long-term side effects reported by the inmates 
included pain during sexual intercourse, difficulty maintaining erections, and 
testicle shrinkage.166 In addition, chromosome damage in testicular cells, po-
tentially caused by the radiation, can cause infertility, increase the possibility 
of testicular cancer, and raise the odds that children will have birth defects.167 
The surviving participants now have various medical problems likely resulting 
from the experiments, including prostate cancer, loss of vision, and vascular 
diseases.168 
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Another infamous prisoner medical experiment emerged from a collabo-
ration between the University of Pennsylvania, Holmesburg Prison, and vari-
ous for-profit laboratories. During the 1950s and 1960s, Dr. Albert Kligman 
used the inmates at Pennsylvania’s Holmesburg Prison as research subjects for 
numerous studies on “acres of [prisoner’s] skin.”169 Dr. Kligman tested 153 
experimental, topical drugs over the span of four years, with approximately 
seventy-five percent of inmates suffering side effects such as baldness, extreme 
scarring, and permanent skin and nail injuries.170 
Kligman’s research studies included tests with “toothpaste, deodorant, 
shampoo, skin creams, detergents, liquid diets, eye drops, foot powders, and 
hair dye,” all applied to the skin, with painful results and frequent biopsies.171 
Dow Chemical paid Kligman $10,000 to test dioxin, a component of Agent 
Orange, on inmates’ skin.172 
Even more troubling, many of the Holmesburg prison experiments were 
conducted on individuals who were not yet convicted. More than half of the 
inmates in Philadelphia prisons at the time were individuals awaiting trial or 
trying to make bail.173 The prisoners were so desperate for money that they 
signed up for Kligman’s experiments in droves.174 
Profits were a common motive in prisoner experiments. In the early to 
mid-sixties, inmates in Alabama, Arkansas, and Oklahoma prisons175 were 
used in poorly designed blood-plasma trials, which studied transfusions using 
large amounts of plasma, or plasmapheresis.176 In the Oklahoma prison, a unit 
of blood was removed from each prisoner, the plasma removed, and then the 
remaining cells reinjected.177 Proper sanitary measures were not kept and, at 
one institution, twenty-eight percent of the subjects developed hepatitis.178 In-
stances of transfusions of the wrong blood types were reported and an unde-
termined number of other inmates died from these procedures.179 Although the 
plasma experiments eventually ceased, Dr. Austin Stough, who oversaw the 
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research, personally profited to the tune of over $2 million.180 The prisoners 
were a critical part of both industry profitability and scholarly achievement.181 
By the 1970s, the types of human medical experiments that took place in 
correctional facilities were divisible into three general categories: “behavior 
modification research conducted by prison officials; biomedical research, often 
supported or directed by federal agencies; and pharmaceutical research, largely 
funded and controlled by private drug companies.”182 In 1972, officials from 
the U.S. Food and Drug Administration (FDA) estimated that over ninety per-
cent of investigational drugs were tested on prisoners as a first step,183 whatev-
er the level of consent. 
Following the 1972 media exposure of the Tuskegee syphilis experi-
ment,184 Congress passed the National Research Act in 1974.185 The Act creat-
ed the National Commission for the Protection of Human Subjects of Biomed-
ical and Behavioral Research, which was tasked to develop guidelines for the 
ethical conduct of research.186 The Commission essentially forbade medical 
research on prisoners, with two main concerns in mind: (1) whether prisoners 
bear an equitable share of the burdens arising from the research, and (2) 
whether prisoners have the capacity to give their full and free consent.187 In 
theory, the only research that is now permitted in correctional facilities is that 
deemed minimal-risk.188 
Under current FDA regulations, all research involving human subjects 
must go through an Institutional Review Board (IRB).189 An IRB190 is an ap-
propriately constituted group that has been formally designated to review and 
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monitor biomedical research involving human subjects.191 In reality, however, 
modern human experimentation is regulated haphazardly by a “crazy-quilt of 
hortatory codes and maxims, scattered federal laws and regulations,”192 and 
IRBs. Indeed, “IRBs as currently constituted do not protect research subjects 
but rather protect the institution and the institution’s investigator.”193 
Our standard history of human medical experimentation traditionally ends 
in the 1970s, particularly for non-therapeutic human subject experimentation. 
My research illustrates, however, that this narrative is incomplete. As I explore 
in the next Part, medical research on captive, vulnerable populations continues 
in the twenty-first century. 
II. EUGENICS, MEDICAL EXPERIMENTATION, AND DRUG  
TESTING IN THE 21ST CENTURY 
Why does the captive subject remain such a popular body upon which to 
practice medical experiments? As discussed in Part I, the history of experi-
menting on the incarcerated and institutionalized arose at the same time that 
both the institution and the correctional facility were born.194 Those individuals 
incarcerated in correctional facilities were “vulnerable, stigmatized, and ex-
pendable,”195 frequently poor, uneducated, and largely belonging to minority 
groups.196 All of these captive, vulnerable individuals have continued to prove 
irresistible to doctors and researchers hoping to perform human subject re-
search. 
Some minimal federal oversight over human subject research is provided 
by the Policy for the Protection of Human Subjects, 45 C.F.R. § 46, which reg-
ulates the type of experiments that may be performed upon vulnerable popula-
tions.197 In most general terms, the policy applies to all research involving hu-
man subjects that is conducted, supported, or otherwise subject to regulation 
by any federal department or agency.198 
The policy is divided into four subparts: subpart A, also known as the 
“Common Rule”; subpart B, additional protections for pregnant women, human 
fetuses, and neonates; subpart C, additional protections for prisoners; and sub-
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part D, additional protections for children.199 The policy, however, only applies 
to those federal agencies that choose to adopt it.200 In addition, the Common 
Rule does not apply to any research not funded or conducted by specified federal 
sources.201 As detailed below, this leaves substantial room for some very ques-
tionable human subject research. 
A. Correctional Facilities 
Medicine has always claimed a “special provenance” over crime and the 
criminal,202 a provenance that is tightly intertwined with the history and prac-
tice of eugenics.203 Given that such a despised, overlooked set of subjects sits 
captive in an easily accessed institution, it should be of no surprise that prison-
ers remain the most popular set of individuals upon which to test various med-
ical theories, dangerous materials, and pharmaceuticals. 
Today’s inmates are still desirable for medical experimentation due to the 
structure of the federal regulation of most medical therapies.204 At the most 
basic level, federal regulations require that any medical experimentation on 
humans take place in three formal phases: Phase I, which asks about the safety 
of treatment; Phase II, which continues to evaluate safety while also asking 
about effectiveness of the treatment; and Phase III, which compares the treat-
ment to the standard treatment.205 Phase I requires healthy subjects to test both 
the safety and efficiency of any treatment, whether pharmaceutical or interven-
tional, and accordingly is the most dangerous, due to side effects and unknown 
results.206 Because of the difficulties of Phase I testing, most medical research-
ers prefer that their subjects be in closed facilities, where they can be carefully 
tracked and monitored.207 Accordingly, those individuals who are incarcerated 
long term—whether in alternative correction locations or formal correctional 
facilities—remain the medical researcher’s ideal subject, despite the regula-
tions that currently surround prison research.208 
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The list of medical experiments currently occurring in correctional facili-
ties is long, and I discuss only a representative subset below. These experi-
ments are not confined to prisons; such research takes place in all sorts of cor-
rectional control facilities, including drug addiction treatment centers.209 These 
human medical experiments are overseen by private contractors and are fre-
quently just beyond the reach of governmental regulation.210 Such research all 
too often manages to elude regulation.211 
Indeed, the majority of research involving prisoners occurs outside the 
purview of the requirements of 45 C.F.R. § 46.303, subpart C.212 Research in-
volving vulnerable populations applies only to research that includes “any in-
dividual involuntarily confined or detained in a penal institution.”213 Accord-
ingly, any prisoner studies that do not take place in a formal correctional facili-
ty are being conducted without review or approval by an IRB.214 
1. Alternative Corrections 
Both public universities and drug companies regularly use prisoners and 
other incarcerated individuals as subjects in medical experiments.215 More than 
one-third of these medical experiments take place in alternative corrections 
facilities, which include probation, residential drug treatment programs, parole, 
community corrections, home confinement, and boot camps for first-time drug 
users and sellers.216 
Most recently, in both 2006 and 2008, the drug company Hythiam entered 
into contracts with five different states to recruit addicted prisoners into an ex-
perimental drug addiction treatment program.217 State courts diverted defend-
ants with drug charges into an experimental treatment program called Prometa, 
which included thirty days of three different experimental drugs prescribed off-
label.218 The pharmaceuticals consist of gabapentin, an anti-seizure medica-
tion; flumazenil, which is used as an antidote in the treatment of benzodiaze-
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pine overdose; and hydroxyzine, an antihistamine.219 The Prometa protocol 
costs approximately $15,000 per participant, and has been touted as a revolu-
tionary cure-all for a myriad of addictions.220 Prometa, however, is not FDA-
approved as an addiction therapy, nor has it undergone extensive scientific test-
ing.221 
In 2006, Prometa was used in a forty-person pilot program in a Pierce 
County, Washington felony drug court through a nonprofit treatment center.222 
Initially, officials reported very promising results.223 Due to the pilot program’s 
success, Pierce County was able to obtain $800,000 for Prometa funding in 
both the state and county correctional facilities in 2007.224 The Pierce County 
Council ended the Prometa funding, however, after a report by auditors con-
cluded there was no evidence it actually worked.225 
Prometa’s manufacturer, Hythiam, aggressively marketed the drug com-
bination to the numerous drug courts that offer treatment to offenders as an 
alternative to going to jail.226 But a number of its pilot programs in various 
state and county drug courts, while deemed successful initially, had mixed re-
sults when further scrutinized.227 In Pierce County, for example, the nonprofit 
clinic administering the drug combo made its results look far better than they 
were, often by failing to count the probationers who dropped out of the pro-
gram or were imprisoned.228 Ultimately, those given Prometa treatment did not 
have better outcomes than those given a placebo in terms of reducing metham-
phetamine use, retention in treatment, or reducing methamphetamine crav-
ings.229 
Another drug addiction treatment, Vivitrol (extended release naltrexone), 
is currently being tested on pre-release and released prisoners through a study 
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sponsored by the Friends Research Institute.230 Vivitrol is a prescription inject-
able medicine used to treat opioid and alcohol dependence after detoxifica-
tion.231 As a non-opioid-based treatment for opioid addiction, Vivitrol is popu-
lar for use in prisons and drug courts, and has been repeatedly tested in crimi-
nal justice settings. 232 Vivitrol is produced and marketed by a for-profit drug 
company, Alkermes Inc.233 
In 2011, Alkermes initiated a three-year clinical research study on the ef-
ficacy of Vivitrol. Over a period of six months, the company injected it month-
ly into prisoners scheduled for release in three Maryland prisons.234 Out of the 
twenty-seven parolees enrolled in the study, seven had serious, adverse effects 
from the injections, including anaphylactic reactions and abscess at the injec-
tion site.235 Twenty-six out of twenty-seven participants had other side effects, 
including blood and lymphatic system disorders, gastrointestinal disorders, and 
urinary tract infections.236 
The issues with testing Vivitrol on inmates are multi-fold. First, using 
Vivitrol requires that the patient be fully opioid-free for at least two weeks be-
fore beginning treatment. Thus, any relapse of drug use while taking Vivitrol 
can be very dangerous, as there is the possibility of accidental overdose, seri-
ous injury, coma, or death.237 Additionally, other serious side effects include 
severe reactions at the injection site, such as tissue damage necessitating sur-
gery or tissue death, and suicidal thoughts.238 
Because Vivitrol is such a new drug, there is little empirical evidence that 
supports its use.239 There have only been five trials testing Vivitrol’s impact on 
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opioid addiction, most of which have been small and industry-funded.240 Alt-
hough Vivitrol has been approved by the FDA for opioid treatment, the ap-
proval was based on a single trial in Russia, where the requirements for drug 
efficacy and safety are far looser.241 The one existing study comparing bupren-
orphine versus Vivitrol concluded that both are equally effective in preventing 
relapse—that is to say, not very effective.242 There have been studies showing 
high dropout rates, as well as ones finding that the subjects returned to opioid 
use while taking Vivitrol or after going off it.243 Thus, prisoners or convicted 
offenders participating in drug court programs are literally experimental sub-
jects for Vivitrol’s maker. 
Alkermes has been heavily lobbying criminal justice policymakers to 
make their treatment the only one available to pre-release and released prison-
ers who need addiction treatment.244 This would mean that prisons, jails, and 
drug courts could force addicts to take Vivitrol as their only alternative to in-
carceration.245 Alkermes has been extremely active at the state level, where 
most decisions about drug treatment and alternate corrections are made.246 In 
2016 alone, the company spent $4.4 million on federal lobbying; not coinci-
dentally, 2016 sales for Vivitrol were $209 million, and Alkermes predicts that 
sales could reach $1 billion by 2021.247 
Alkermes has marketed directly to drug court judges and correctional fa-
cilities, including halfway houses, to push its product.248 For example, at least 
eight drug courts in Indiana only allow Vivitrol as an opioid addiction treat-
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ment, excluding any other medication.249 Vivitrol is two to three times as ex-
pensive as other, generic treatments, such as methadone and buprenorphine.250 
The multiplicity of problems with Vivitrol makes it unsuitable for use in 
medical research studies or as a required medication for pre-release prisoners, 
parolees, individuals on probation, and residents in drug court-ordered halfway 
housing. Nonetheless, Vivitrol has been routinely and repeatedly tested on in-
mates, and its use is sometimes required for individuals to be eligible for par-
ticipation in certain drug courts.251 Given the serious side effects, expense, and 
uncertain efficacy of the drug, this kind of medical experimentation with those 
in the state criminal justice system is unacceptable. 
2. Modern Medical Experiments in Prisons 
Despite the federal rules and regulations in place, a surprisingly large 
amount of medical research takes place in correctional facilities, involving 
both children and adults.252 Medical experimentation on the incarcerated is 
alive and well. 
As the corrections population has increased to almost 7 million individu-
als,253 this captive group has offered an irresistible subject pool to drug com-
panies and medical test clinics. In prisons and jails alone, the number incarcer-
ated has expanded to approximately 2.1 million, with the rest of the growth 
taking place during probation, parole, and other correctional alternatives.254 
The majority of research involving prisoners occurs outside the purview 
of 45 C.F.R. § 46, subpart C, which regulates the type of experiments that may 
be done to vulnerable populations.255 Subpart C regulations protecting prison-
ers do not extend to the vast majority of prison research participants.256 In ad-
dition, many prisoner experiments are being conducted without either review 
or approval by an IRB.257 The primary protection prisoners have from abusive 
medical research “hangs on a single thread, on a single federal regulation in 
                                                                                                                           
 249 See id. 
 250 See Lopez, supra note 244. 
 251 Szalavitz, supra note 240. 
 252 See Gordon et al., supra note 230 (explaining one recent experiment conducted on prisoners). 
 253 INST. OF MED. OF THE NAT’L ACADS., supra note 212, at 58. 
 254 See id. 
 255 Under 45 C.F.R § 46.306(a)(2), prisoners may only be included as subjects when the research 
involves one of the following four categories: (i) a study of criminal behavior and studies of possible 
causes and effects; (ii) a study of prisons as institutional structures or of prisoners as incarcerated 
persons, with only minimal risk allowed; (iii) research on conditions particularly affecting prisoners as 
a class (permitted only after consultation with the Secretary of the Department of Health and Human 
Services (DHHS)); (iv) research on practices to improve the health and well-being of the subject 
(permitted only after consultation with the DHHS Secretary). 
 256 See INST. OF MED. OF THE NAT’L ACADS., supra note 212 at 30, 66. 
 257 Id. at 30. 
28 Boston College Law Review [Vol. 61:1 
federally funded research only.”258 There is also no central location for infor-
mation about the amount and kind of prisoner research done, thereby making 
the tracking of such information extremely difficult.259 
There have been numerous clinical trials and experimental therapies that 
not only violate the law but also subject inmates to inhumane medical risks.260 
Indeed, conducting research on individuals has become an enterprise, and the 
incarcerated, now as always, present a perfect confined set of subjects.261 
In 2000, for example, the federal Office of Human Research Protections 
(OHRP) called off a variety of federally funded human experiments, all run by 
the University of Texas.262 The university had failed to follow federal regula-
tions aimed at protecting research-study volunteers.263 Of the roughly 300 ex-
periments suspended at the time, 195 involved Texas prisoners, with most test-
ing HIV/AIDS drugs.264 
Universities often pair up with prisons to run experiments. In 1997, Dr. 
Hans Steiner, a Stanford psychiatrist, conducted an experimental drug trial on 
juvenile offenders held by the California Youth Authority (CYA).265 Steiner 
administered Depakote, a seizure disorder medication, to sixty-one young men, 
aged fourteen to eighteen, to see if the drug would reduce tendencies toward 
violent behavior.266 The Stanford IRB approved the research, allowing the 
CYA to consent for any children whose parents could not be reached after thir-
ty days.267 Like all psychotropic medications, Depakote can have serious side 
effects, including serious liver damage, inflammation of the pancreas, bleed-
ing, high blood ammonia levels, and suicidal thoughts and actions.268 
The Stanford CYA Depakote experiment illustrates the problem with rely-
ing on state statutes and various regulatory bodies to regulate such medical 
experimentation on children. In California, a “tangled, contradictory web of 
state and federal laws govern[s] medical research on prisoners and chil-
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dren.”269 One state statute directs that “[b]iomedical research shall not be con-
ducted on any prisoner in this state.”270 But another statute, passed to allow 
inmates access to experimental HIV and AIDS medications,271 allows prisoners 
to be prescribed “investigational new drug[s]” that are only available through 
treatment protocols if it is in “the best medical interest of the patient . . . .”272 
These loopholes mean improper human subject research can flourish unno-
ticed. Given the multiple cracks in the system for oversight of prisoner re-
search, we need stronger, more absolute controls on such medical experimenta-
tion on inmates. 
B. Children 
Children, whether imprisoned or otherwise captive, are another tempting 
target for human medical research. This is especially true when parental con-
sent concerns are either abrogated or diminished. 
1. Wards of the State 
Medical research on infant state wards is minimally regulated.273 Most 
wards of the state are children who have been removed from their parents due 
to mistreatment or abandonment, when legal custody of the child reverts to the 
state.274 These children primarily live in foster family homes, although approx-
imately nineteen percent live in institutions or group homes.275 The abuse and 
neglect already suffered by wards of the state should not be further exacerbated 
by inappropriate medical research experimentation.276 
The medical research conducted by the National Institutes of Health 
(NIH), testing AIDS drugs on foster children, shows the harms that can arise 
without careful oversight. For fifteen years, beginning in the 1990s, various 
scientific researchers tested AIDS drugs on hundreds of foster children in stud-
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ies funded by the NIH.277 The research studies were administered in seven 
states—Illinois, Louisiana, Maryland, New York, North Carolina, Colorado, 
and Texas—and involved more than forty-eight separate experiments.278 The 
ages of the foster children enrolled ranged from infants to the late teens.279 
Several of the experiments using enlisted foster children were very risky, 
involving early Phase I280 and Phase II281 research to determine side effects and 
safe dosages, so children could begin taking adult AIDS medicine cocktails.282 
Many of the children had to be forced to take the medicines, which routinely 
caused vomiting and diarrhea, and those who refused were often put on stom-
ach tubes to force the medications.283 
Due to the toxicity and strength of the drugs, several of the foster child 
experiments reported serious side effects such as “rashes, vomiting and sharp 
drops in infection-fighting blood cells,” particularly when the children took 
experimental antiretroviral drugs in the hopes of suppressing AIDS, or tried 
other experimental medicines to treat secondary infections.284 One experiment, 
which administered high doses of an experimental drug to the children, had a 
disturbingly high death rate.285 A safe and effective dose was never deter-
mined.286 
Very few of these foster care children received advocates or independent 
monitors to oversee their needs, despite the research institutions’ promise to 
provide them.287 Moreover, NIH failed to track whether children were appoint-
ed advocates, leaving the decision up to volunteer medical review boards at 
each research study location.288 Some of the experimenters believed that chil-
dren as young as five were old enough to provide their consent.289 In addition, 
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the foster and/or biological parents were not always consulted before the 
treatments were prescribed.290 
At the end of these experiments, only some of the drugs were approved 
for children, while others were rejected due to their toxicity and troubling side 
effects.291 In one research experiment testing dapsone, for example, “at least 
ten children died from a variety of causes, including four from blood poison-
ing.”292 
Further, the funding from the NIH was premised on testing experimental 
AIDS drugs and vaccines on a wide range of children in foster care, including 
infants and children who were only “presumed” to be HIV-infected.293 This 
was justified on the basis of one researcher’s finding that “[t]he incidence of 
transmission of HIV from an infected mother to her offspring is estimated to 
be in the range of 5%–40%.”294 Accordingly, foster children who may never 
have developed AIDS were given drugs that had fatal risks and severe adverse 
effects, all for non-therapeutic purposes.295 
Finally, several HIV vaccines were tested on children without HIV. One 
of the reports resulting from the study of an experimental AIDS vaccine noted 
that 125 immunized children were not infected with HIV.296 Another study, 
testing two experimental vaccines, acknowledged that 157 newborn infants 
were sought and utilized.297 
Clinical trials testing brand new pharmaceuticals on foster children con-
tinue to take place today. In 2009, seven-year-old Gabriel Myers, who had 
been prescribed Vyvanse and Symbyax, took his own life in his Florida foster 
home.298 Gabriel was among a number of Florida foster children enrolled in 
pharmaceutical clinical trials by his doctor, Dr. Sohail Punjwani.299 
Neither informed parental consent nor judicial authorization for adminis-
tering psychotropic medications was obtained for the foster children participat-
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ing in the drug trial.300 Following an investigation into the death, Florida 
banned the use of foster children in clinical drug trials, over the protest of the 
FDA.301 Despite the ban, however, Psychiatric Solutions, a Florida residential 
treatment programs operator, successfully added an amendment to the ban al-
lowing the administration of “mental-health drugs to young foster children for 
three days without the consent of a parent or judge.”302 
Policies for enrolling foster children into clinical drug trials vary by state 
and county.303 Many child psychiatrists who treat foster children have close 
ties to the pharmaceutical industry and have received serious financial in-
ducements to prescribe mood-altering pharmaceuticals, especially anti-
psychotic drugs. There are tremendous amounts of money available to pediat-
ric drug researchers, and with industry funding comes great pressure on the 
researchers to speedily produce results.304 
Between 2010 and 2013, for example, pharmaceutical companies gave 
$14 million to psychiatrists treating California foster children.305 California’s 
foster care doctors received double the payment of the average California doc-
tor during that time.306 Unsurprisingly, the doctors who prescribed the most 
antipsychotics and other psychotropic medication received the most money.307 
Between 2010 and 2013, one doctor in southern California, Bhatia Prakash, 
received over $2.58 million for “research,” and another, Steven Volk, received 
over $2.18 million for the same.308 A large portion of this “research” money 
went to funding clinical trials to test psychotropic drugs on foster children.309 
Seven of the twenty-five California doctors with the highest prescription 
count in this period were conducting research for psychotropic drug compa-
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nies.310 Many of these drugs have severe side effects. For example, Zyprexa, a 
common psychiatric medication created to treat severe mental illness, which is 
often prescribed for child behavior problems, can lead to weight gain, exacer-
bation of diabetic conditions, and tardive dyskinesia,311 which can be irreversi-
ble.312 
This use of foster children as unwitting participants in clinical trials is 
particularly disturbing, given that almost twenty-five percent of California fos-
ter care adolescents are prescribed psychotropic medications.313 Often these 
medications are prescribed to control unwanted behavior instead of severe 
mental illness, the only condition for which the drugs are approved.314 Foster 
children do not have to consent to the use of these medications.315 These chil-
dren are viewed as “the bottom of the ladder in our society,” so it is unsurpris-
ing that “[t]he experimentation, the drug cocktails, the first-line drugging typi-
cally starts with the group that’s the least protected.”316 
Over the past five to ten years, investigations in five states have uncov-
ered that hundreds of foster children were prescribed excessive doses of vari-
ous psychotropic drugs.317 These prescriptions were also given to younger 
children, even though there is no evidence to support such a use.318 These fos-
ter children represent attractive subjects to drug companies because they are a 
“captive audience:” either the foster parent or staff member ensures that the 
child takes the pills, thereby eliminating any compliance issue in long-term 
testing or research.319 
Many powerful anti-psychotic drugs are prescribed to foster children to 
treat behavior problems, which is an off-label use not approved by the FDA.320 
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The majority of these psychotropics comes with serious side effects, including 
“breast growth in boys, cardiac arrest, extreme weight gain and diabetes.”321 
Often one anti-psychotic is prescribed in tandem with another, and for long 
durations of time, not just as emergency short-term measures.322 These anti-
psychotics are prescribed to children in foster care at a disproportionate rate, 
frequently for children diagnosed with attention deficit and hyperactivity dis-
order (ADHD), instead of schizophrenia or bipolar disorder, for which these 
psychotropics are specifically designed.323 There is little evidence supporting 
the use of antipsychotics for treatment of ADHD in children.324 
Overall, both the NIH and its OHRP have worked to create “greater par-
ticipation of children in research, despite general concerns regarding human 
subjects’ protections more generally.”325 This is a reversal of the traditional gov-
ernment policy of “children last.”326 When applied to highly vulnerable and cap-
tive children, this new policy is untenable—there is seemingly no one standing 
at the helm. 
2. Extreme Poverty and Critical Illness 
Children who are in extreme poverty or suffering from critical illness 
should also have scrupulous regulation overseeing any medical research per-
formed on them, as they also consist of a captive population: captive in either 
their hospital or impoverished/dangerous surroundings. Like foster children, 
these vulnerable children need special protection from medical research that 
uses them in non-therapeutic ways. 
a. Extreme Poverty 
In 1992, the New York State Psychiatric Institute and Mt. Sinai Medical 
School enrolled approximately 150 young minority boys for a clinical trial 
testing the effect of a drug on children with ADHD.327 Some of the boys were 
younger siblings of children adjudicated as juvenile delinquents.328 These chil-
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dren were identified through court records from the New York Department of 
Probation, as well as by interviews of parents to find those who used ‘‘adverse 
rearing practices.’’329 The parents were paid $125 for their children’s participa-
tion.330 The boys were given fenfluramine,331 and they had their neurochemical 
responses recorded in an effort to prove a theory linking aggression to a bio-
logical marker.332 After an outcry, federal medical ethics researchers criticized 
Mt. Sinai and the Research Foundation of City University of New York, but no 
charges were filed.333 
The Kennedy Krieger Institute (KKI), a Johns Hopkins-associated facility 
for disabled children, was similarly accused of exposing poor black children to 
“dangerous lead hazards” during a housing study.334 KKI promised to help 
parents find “lead-safe housing” for their lead-poisoned children, and simulta-
neously enrolled them in a research study.335 Yet researchers knew that the 
housing in which the families were placed by KKI was itself imbued with poi-
sonous lead. As the class action lawsuit charged: 
Children were enticed into living in lead-tainted housing and sub-
jected to a research program which intentionally exposed them to 
lead poisoning in order for the extent of the contamination of these 
children’s blood to be used by scientific researchers to assess the 
success of lead paint or lead dust abatement measures . . . . These 
children’s health was put at risk in order to develop low-cost abate-
ment measures that would help all children, the landlords, and the 
general public as well.336 
The lawsuit alleged that no medical treatment was provided for the children in 
the study, and exposure to the lead caused permanent neurological injuries in 
some of the children.337 
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Additionally, as the class action argued, the consent agreements signed by 
the parents did not contain a full explanation of the research, which was specif-
ically designed to test the lead abatement process by checking how much the 
children’s blood continued to be contaminated.338 “Lead-safe” was never de-
fined in the consent form, but a reasonable person would have likely inferred 
that the housing provided was safe from lead threats to children.339 In 2001, the 
Maryland Court of Appeals analogized KKI’s role in the lead-poisoning study 
to the Tuskegee syphilis study.340 Lawsuits are still pending against the Kenne-
dy Krieger Institute for its actions. 
b. Critical, Life-Threatening Illness 
Medical experiments have also been performed on severely premature in-
fants without proper parental consent. In 2013, the U.S. Department of Health 
and Human Services investigated a research study involving blood transfusions 
for very premature infants.341 The study tested when blood transfusions should 
be given to treat anemia. Premature babies were randomly assigned to either 
one group receiving transfusions for mild anemia, or a second group receiving 
transfusions only for severe anemia.342 The point of the study was to determine 
the best method for preventing deaths and brain damage.343 The study was 
conducted by the Neonatal Research Network, a collaborative effort between 
academic medical center neonatal intensive care units across the United 
States,344 and funded by NIH.345 
Public Citizen, a consumer advocacy organization that reviews human 
medical experiments,346 found two problems with the study. First, the research-
ers failed to inform parents of the risks inherent in pursuing an alternative meth-
od of treatment, as opposed to the standard care procedures.347 The parental con-
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sent form also failed to disclose that the restrictive transfusion group—where 
blood was only transfused at the danger point—was riskier than being in the oth-
er group.348 In addition, all the consent forms contained misleading information 
that equated participation in the study with receiving customized care for the 
infant, with most forms indicating that the trials had no risk.349 In other words, 
the parental consent forms did not allow the signers to make a truly informed 
decision.350 
Second, the design of the infant blood transfusion study failed to set up a 
comparison group receiving the typical customized care, a standard aspect of 
most modern research trials.351 The study also failed to provide a clear descrip-
tion of the standard transfusion practices at the participating hospitals.352 Pub-
lic Citizen argued that these failures made adequate safety monitoring impos-
sible, and accordingly, the risks to the premature infants were neither mini-
mized nor reasonable.353 
These deviations from the regular standard of care and proper use of in-
formed consent in infant research studies are not uncommon. From 2005 
through 2009, a research study known as SUPPORT (Surfactant, Positive Pres-
sure, and Oxygenation Randomized Trial) was performed on 1,316 premature 
infants who had breathing problems due to their early arrival.354 The infants 
were divided into two groups: one group provided with high blood oxygen 
levels, which can increase the risk of blindness, and one group provided with 
lower blood oxygen levels, which can increase the risk of neurodevelopmental 
disorders and death.355 
The researchers used “experimental measuring devices” with the intention 
of blinding the caregivers from knowing the babies’ actual oxygen levels. 
Moreover, the parents were never informed.356 This was done in the name of 
making the study more “rigorous.”357 The experiment’s researchers also told 
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the patients’ parents that the study did not have any special risk, because all the 
procedures carried out represented standard care.358 This was untrue.359 
Despite this serious failure in transparency for the participants, the issue-
laden consent forms were reviewed and approved by all twenty-three medical 
center ethics committees involved, including those from Stanford, Yale, Duke, 
and Tufts.360 The parents of the 1,316 infants were never informed that the 
study carried increased risks of blindness, brain damage, and death to their 
newborn children.361 
Recurring abuses of the most vulnerable populations of children illustrate 
how the current loose set of regulations and oversight are insufficient to protect 
the defenseless, particularly when there is more than a minimal risk of harm. 
The scientific and medical community is simply not able to police itself when 
it comes to medical experimentation on vulnerable children.362 
C. Psychiatric Institutions 
Despite the variety of laws and statutes theoretically preventing the use of 
the mentally ill in medical experimentation, the practice still continues. Many 
psychiatric researchers “mistreat mentally ill [patients] in ways that would . . . 
provok[e] outrage . . . in other areas of medicine.”363 
Some of the most troubling experiments have been the “symptom provo-
cation” or “challenge” studies, where previously stable mentally ill patients 
were given amphetamines, ketamine, or other psychoactive drugs to provoke a 
psychiatric episode.364 These experiments typically had a long-lasting, negative 
effect on the patients, because after a relapse—particularly a first relapse fol-
lowing an initial psychotic break—some patients never return to the same level 
of mental health.365 In addition, schizophrenic patients tend to suffer signifi-
cantly higher rates of self-harm and suicide during a relapse.366 Repeated psy-
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chotic relapses for a schizophrenic patient very frequently lead to a worse 
long-term outcome.367 
The sole purpose of these challenge experiments was to induce psychosis 
in the patients for the benefit of the researchers.368 These researchers, in phar-
maceutical experiments conducted nation-wide, have repeatedly failed to in-
form their mentally ill patients of the risks inherent in these studies, thus keep-
ing their patients in the dark as to the true purposes of the research.369 Conse-
quently, the researchers cannot possibly obtain proper consent.370 The symp-
tom-provocation experiments at the University of Maryland, University of Cal-
ifornia Los Angeles, and the National Institute of Mental Health have used 
similarly faulty informed consent mechanisms.371 
Likewise, Yale University researchers performed experiments that sub-
jected stable schizophrenia patients to psychotic relapse in an amphetamine 
provocation experiment, in conjunction with a Veterans Affairs (VA) hospi-
tal.372 The men, in one instance, were injected with m-chlorophenylpiperazine 
to induce psychosis.373 These injections exacerbated the patients’ delusions and 
hallucinations374 Yale also recruited schizophrenic patients for experiments 
where the individuals were hospitalized, their medications halted, and they 
were then given infusions of “tetrahydrocannabinol, the psychoactive ingredi-
ent in marijuana.”375 
As a whole, medical experiments on the mentally ill, particularly those 
who are confined, are underregulated, and often veer into the unethical. In 
Georgia, for example, Drs. Richard Borison and Bruce Diamond tested multi-
ple psychiatric drugs on schizophrenic patients, using all sorts of inducements 
to get them to agree to testing.376 Dr. Borison, who was the chief of psychiatry 
for the Augusta VA Hospital, hired mainly female staffers to coax schizophren-
ic patients into consenting to the trials by, for example, offering cigarettes to 
patients in locked wards in exchange for participation.377 Such a travesty of 
informed consent has no place in modern medical research. 
Similarly, in 1995, a New York state trial court ordered the New York 
State Health Department to cease conducting hundreds of experiments on vul-
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nerable patients deemed to be incompetent to give consent.378 The 400 ongoing 
New York psychiatric experiments, costing roughly $52 million, were overseen 
by the New York Office of Mental Health and involved hundreds of institu-
tionalized psychiatric patients who were undergoing experimental drug treat-
ments for a variety of mental illnesses.379 
In many of these cases, it was the relatives and friends of the patients who 
had given their consent, not their parents or guardians.380 The court order halt-
ed all experiments on adult psychiatric patients who were unable to give con-
sent, nontherapeutic experiments on children, and experiments where the 
child’s parents had not given consent.381 
The New York appellate court upheld the trial court’s order, holding the 
regulations allowing such medical experimentation without proper consent to 
be invalid.382 The court made clear that New York could no longer administer 
“experimental antipsychotic and psychotropic drugs, which are capable of 
causing permanent harmful or even fatal side effects[, or use] highly invasive 
painful testing procedures on subjects,”383 particularly when the experiments 
lacked therapeutic benefit. 
In addition, the court found that the preparation phase of the research 
study was untenable.384 Several of the studies involved required a medication-
free or placebo phase, where the subjects swapped their current medication for 
an experimental medication, frequently causing relapse and adverse symp-
toms.385 The court specifically noted the “cost in human pain and suffering to 
those subjects who are not capable of expressing either their consent or objec-
tion to participation[.]”386 
Using mentally ill patients in medical research studies continues. Between 
2002 and 2005, three anti-psychotic drugs were tested out on psychiatric inpa-
tients, at least one of whom was enrolled in the trial involuntarily or without 
consent.387 Known as the Comparison of Atypicals in First Episode of Psycho-
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sis, or CAFE study,388 the medical experiment was funded by AstraZeneca, the 
manufacturer of Seroquel, and done in partnership with the University of Min-
nesota.389 The research trial required 400 patients in the midst of their first 
psychotic episode to take an assigned anti-psychotic drug for a complete 
year.390 
The CAFE study had serious risks. It required patients to stay on their as-
signed drug, regardless of its therapeutic success or lack thereof.391 In addition, 
the experiment strictly limited access to drugs needed to ease the very serious 
side effects and symptoms of the trial drugs.392 
At least one of the patients was enrolled in the anti-psychotic study with-
out proper consent. On November 12, 2003, Dan Markingson was involuntari-
ly hospitalized for psychosis and mood disorder by Dr. Stephen Olson, and was 
judged unable to make decisions about his medication.393 On November 20, 
2003, however, Dr. Olson changed course and asked the court to temporarily 
suspend the involuntary commitment of Markingson.394 The next day, Mark-
ingson was enrolled in the CAFE study by a social worker.395 Dr. Olson was 
one of the lead researchers in the study.396 
Markingson was now judged capable of consenting to a clinical trial of 
antipsychotic medications.397 The consent form was read to Markingson out 
loud, and he allegedly consented.398 
Clinical trials of antipsychotic drugs do not typically allow patients with a 
risk of suicide or violence to participate, in order to reduce the likelihood that 
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they will harm themselves or others during the experiment.399 Here, however, 
the CAFE trial did allow patients who presented such risks to enroll.400 This 
included Markingson.401 The study had poor enrollment numbers and was fac-
ing probation, so it is likely there was some pressure to recruit questionable 
patients.402 
Despite Markingson’s mother’s protestations about her son’s enrollment 
in the clinical trial, she was unable to remove him from the experiment, or 
change his medication protocol.403 No surrogate decisionmaker was ever ap-
pointed for Markingson.404 Approximately six months later, when he was still 
part of the CAFE medication trial, Markingson died by suicide in his halfway 
house.405 
By the time the CAFE medical trial concluded, there were eighteen “seri-
ous adverse events” reported from the 400 patients, including an alleged homi-
cide, three suicide attempts, and two deaths by suicide (both by patients taking 
Seroquel).406 As part of the clinical trial, AstraZeneca paid the University of 
Minnesota Psychiatry Department $15,648 for every patient who completed 
the CAFE study. This amounted to $327,000 in revenue for the Department.407 
Minnesota also required the study coordinator for the CAFE study to do eight-
een hours of continuing education as part of a “corrective action” for enrolling 
patients without full consent.408 In 2015, the University of Minnesota halted 
patient enrollment in all psychiatric drug studies after being criticized in a state 
report for its handling of the Markingson suicide.409 
Clinical trials continue on both adult and adolescent inpatients with se-
vere depression and suicidal ideation. Janssen Laboratories, a subsidiary of 
Johnson & Johnson, is currently running research studies using intranasal es-
ketamine (aerosolized ketamine) on inpatient adolescents and adults who are 
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suffering from severe, treatment-resistant depression and are at imminent risk 
for suicide.410 In one clinical trial currently being performed at Yale University, 
adolescents between twelve and seventeen are testing intranasal esketamine, 
comparing the reactions to adolescents taking a psychoactive placebo (oral 
midazolam).411 The intranasal esketamine will be compared to the midazolam 
to determine which is better at reducing the symptoms of major depressive 
disorder, including suicidal ideation, for those teenagers who are assessed to be 
at imminent suicidal risk.412 
Notwithstanding the promotional efforts of pharmaceutical companies, 
however, it is unclear whether using esketamine instead of the standard anti-
depression drugs to relieve treatment-resistant depression really makes a sig-
nificant difference.413 In addition, the side effects of long-term ketamine use 
for depression are essentially unknown.414 Common side effects of repeated 
ketamine use include urinary tract symptoms, liver toxicity, cognitive changes, 
ulcerative cystitis, neurocognitive deficits in working and episodic memory, 
and dependence.415 
Testing such a potentially addictive drug on inpatient mentally ill adoles-
cents is questionable, particularly because their level of depression may make 
their parents or guardians desperate to try any new treatment, even one with 
significant potential side effects and the possibility of long-term dependence. 
Suicidal teens are another vulnerable population that should be prohibited from 
participating in any human medical experimentation. 
Despite all of these dangers in conducting experiments testing anti-
psychotics and other anti-depressants, such clinical research trials continue, 
particularly when the drugs in question are patented, name-brand medications. 
The financial pressure to test and bring to market new mental illness drugs is 
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intense, given that anti-psychotics are the top-selling class of drugs by reve-
nue.416 “Successful clinical trials are the lifeblood of biotech companies,”417 
because profits depend on the development of new drugs, which require hu-
man medical experimentation. The strong industry desire to experiment on the 
seriously mentally ill should not be permitted, however, particularly when the 
subjects are captive and vulnerable. 
D. Residential Centers for the Disabled 
In November of 2019, the Department of Justice (DOJ) started investigat-
ing whether caretakers at the Glenwood Resource Center, an Iowa residential 
home for the intellectually disabled, had been performing experiments on hy-
dration and sexual arousal upon their patients.418 Many of the residents at the 
residential home are unable to walk, speak, or feed themselves.419 The resi-
dents are medically fragile, and they include both children and adults who are 
physically and/or intellectually disabled.420 “Harmful and uncontrolled human 
subject experiments” are alleged to have taken place at the Glenwood center, 
including one study on sexual arousal of patients and one study on “optimal 
hydration” in treating pneumonia.421 According to reports from guardians of 
residents at the center, Glenwood has not requested permission from parents or 
guardians to perform any such experiments on the residents.422 The DOJ is also 
investigating “inadequate medical, nursing . . . and behavioral health care, 
harmful restraint practices and incidents of needless physical injury.”423 Even 
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in the 21st century, it seems, performing human medical experiments upon the 
captive and vulnerable is still within the bounds of acceptable. 
III. CAPTIVE MEDICAL EXPERIMENTATION GOING FORWARD:  
INFORMED CONSENT, PRIVACY, AND PROFITS 
The severe restrictions on freedom and liberty, as well as the complicated 
role of the medical and drug industries in clinical research, mean that any po-
tential medical research involving vulnerable, captive subjects has tremendous 
challenges.424 
A. Informed Consent 
A patient’s informed consent is required for any medical treatment or pro-
cedure.425 The main goal of informed consent is to protect the autonomy of 
those patients receiving medical treatment or acting as research subjects.426 
Essentially, informed consent requires medical professionals and researchers to 
adequately disclose material information of the proposed treatment so that pa-
tients can make knowledgeable choices.427 More specifically, informed consent 
requires a wide-ranging disclosure of comprehensive information about risks, 
benefits, and alternative forms of treatment.428 Since the 1970s, voluntary in-
formed consent has been a prerequisite to enrolling human subjects for medical 
experimentation.429 The purpose of informed consent is to ensure that potential 
participants have adequate information, relayed in layman’s terms so that the 
subject can voluntarily choose whether to participate.430 
The doctrine of informed consent has been a failure in many ways. Alt-
hough attractive in theory, informed consent has not truly allowed patients to 
make informed decisions about their diagnoses and treatments to match their 
preferences.431 The failure rate for actually understanding informed consent 
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forms is greater than ninety percent.432 Patients cannot express their prefer-
ences if they do not fully comprehend the potential procedures,433 thereby ob-
viating the “informed” aspect of their consent. As Dr. Jay Katz famously noted, 
“informed consent in today’s world is largely a charade which misleads pa-
tients into thinking that they are making decisions when indeed they are 
not.”434 
If attaining true informed consent from human subjects is challenging, it 
is even more difficult in institutional, correctional, or foster care settings. 
Many prisoners have poor reading and communication skills;435 many institu-
tionalized subjects do not have complete cognitive abilities; and foster parents 
are often not fully cognizant of what they are signing. 
Despite the difficulty of obtaining true informed consent, informed con-
sent documents frequently require a college-level reading comprehension.436 
The writing is loaded with medical jargon and frequently uses unfamiliar drug 
terminology, further confusing readers.437 In addition, the extreme length of 
many informed consent forms makes it unlikely they are comprehensively read 
and understood, even by sophisticated readers.438 
There tends to be a communication barrier between medical researchers 
and their subjects, especially when these experiments are non-therapeutic, as 
many drug studies tend to be.439 The potential dangers and risks to the individ-
ual are often unclear, and people too often “trust institutions they know or are 
blinded by hope that they will benefit.”440 
Moreover, when the research results are published, readers of the study 
will take the authors at their word when they assert that the subject consented 
or an IRB approved, even when the validity of that consent is questionable.441 
There is little accountability for the researchers and doctors involved in medi-
cal experiments on vulnerable populations, because there is minimal follow-up 
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on whether patients have truly granted informed consent.442 Further, “what re-
searchers believe to be ethical might not actually fulfill the basic requirements 
of informed consent or ethical research.”443 
The question of informed consent is doubly complicated for those in cor-
rectional facilities. Prisoners tend to have lower levels of education than the 
general population, and are frequently unfamiliar with medicine and health 
care in general.444 
In addition, a high percentage of inmates suffer from serious infectious 
diseases and major psychiatric disorders, both of which might make the com-
prehension of a complicated informed consent form extremely difficult.445 Any 
of these aspects individually prevents an inmate from fully comprehending the 
information relevant to deciding to participate in medical research; serious ill-
ness, whether physical or mental, can limit the capacity of the individual sub-
ject.446 Taken all together, it makes truly informed consent to such experiments 
virtually impossible. 
Further, even when technically granted, an inmate’s consent should not be 
regarded as truly voluntary.447 The structure of life in both jail and prison leads 
to circumstances that erase any ability to realistically consent. In the world of 
correctional facilities, inmates are continually under the threat of duress, and 
thus must always be on alert to comply with directions and follow the rules.448 
Inmates’ physical safety and well-being relies on their ability to listen to those 
who have authority over them.449 Because of their imprisoned status, inmates, 
who by law have many fewer rights, are frequently under “direct or subtle co-
ercion, including risks, threats, or acts of physical and even sexual assault.”450 
This constant coercive pressure limits inmates’ ability to make their own deci-
sions about medical experiments or drug trials because of their powerless posi-
tion.451 
In addition, lack of adequate health care can create a “coercive influ-
ence.”452 Many offenders join investigative trials because it is the only way to 
access medical care.453 
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Patients in mental health institutions also may not be able to fully com-
prehend to what they have consented. The strong likelihood of impaired capac-
ity within this group renders the population especially vulnerable.454 True in-
formed consent can be extremely elusive in such circumstances. Often patients 
are asked to sign a stack of consent forms all at once, without sufficient time to 
read or digest them.455 The sheer volume of the materials raises the question of 
whether any individual, let alone one with serious mental illness, could know 
and understand the contours of the research.456 
The difficulty with obtaining true informed consent persists even with 
less vulnerable populations. A recent study, focused on adult participants in 
cancer clinical trials, found that many subjects “had poor understanding of es-
sential elements of their trial,” despite reading and signing often-elaborate in-
formed consent forms.457 In particular, at least eighty percent of patients were 
not able to respond correctly to three key types of questions in the consent 
form: (1) questions that addressed the experimental nature of their trial thera-
py; (2) questions about the trial’s purported efficacy; and (3) the potential risks 
relative to alternative treatments.458 This was despite the fact that most of the 
patients were “white, native English speakers,” with half having at least some 
college education.459 
Such low levels of comprehension raise serious questions about the quali-
ty of informed consent in many clinical trials, given that these particular pa-
tients should have been able to answer the questions. Part of the problem often 
is the length and complexity of the informed consent forms, because the content 
is frequently shaped with the intent of shielding the research institution and/or 
trial sponsor from liability, rather than focusing on the needs of actual human 
subjects.460 The attempts to shorten and simplify the informed consent forms 
have not really improved comprehension of key elements or associated risks, 
however, despite higher patient satisfaction.461 
In response to these problems, some researchers have advocated getting 
rid of informed consent forms entirely and replacing them with in-person med-
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ical counseling.462 This would involve in-person discussions about the relevant 
risks and benefits inherent in the experimental treatments, as well as the alter-
natives.463 Although in-person discussions would take more time and money, 
this may be one of the few ways to obtain truly informed consent from non-
vulnerable populations. Given the costs, however, such in-depth medical coun-
seling is unlikely to replace consent forms any time soon. 
Vulnerable, captive populations—those people who are incarcerated, in-
stitutionalized, in foster care, living in extreme poverty, or suffering severe 
illness—should not be able to consent to human medical experimentation. 
Many of these patients are viewed as “sickly, unproductive, and unhappy,” and 
thus clinical researchers might see little value in their lives and health.464 The 
patients themselves may nonetheless understandably feel quite differently, 
even if they cannot communicate fully due to cognitive or psychological im-
pairments. We must be especially careful to protect the autonomy and bodily 
integrity of these individuals, along with all other vulnerable, captive subjects. 
B. Privacy and Confidentiality 
Maintaining confidentiality during clinical research and experimentation 
is a critically important component of research ethics.465 Confidentiality and 
privacy require maintaining the anonymity of human research subjects, both as 
a matter of respect to the patient and as a matter of the patient’s comfort in dis-
closing their information when anonymity is promised.466 
The maintenance of confidentiality in research is encouraged by numer-
ous federal research guidance regulations.467 The Health Insurance Portability 
and Accountability Act (HIPAA)468 and the Common Rule govern the infor-
mation collected in clinical trials. The HIPAA Privacy Rule establishes the 
conditions under which protected health information may be used or disclosed 
by covered entities for research purposes.469 As discussed above, the Common 
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Rule governs the ethical conduct of human research in circumstances in which 
the research is federally supported or being conducted by an institution that has 
agreed, in an assurance agreement, to be bound by federal research rules.470 
Under the Common Rule, IRBs have the responsibility for ensuring that feder-
ally funded research adequately protects the privacy of the research subjects 
and maintains the confidentiality of patient data.471 
Violators of the HIPAA Privacy Rule may be subject to civil and criminal 
penalties. These penalties, however, fall primarily on covered entities, such as 
health plans and health care providers.472 The individual researchers themselves 
are not covered by the Privacy Rule,473 and thus may follow it less strictly. 
In addition, patient dignity suffers harm when medical information is 
shared without specific consent.474 This is all the more true for vulnerable, cap-
tive populations, who often are unable to fully grant their consent, or may even 
be seen as not needing or deserving such protection and autonomy. 
Maintaining privacy for a vulnerable, captive subject can be extremely 
difficult. In correctional facilities, confidential health information can often be 
deduced from an inmate’s routine, a cell search, or regular visits.475 In addi-
tion, any health or medical information that would normally be kept private 
may have to be shared with correctional officials to avoid danger or the spread 
of disease.476 
For those individuals who are being treated for mental illness in facilities, 
whether prisons, psychiatric hospitals, or long-term care homes, the sharing of 
private medical information might disclose data that they do not wish to be 
exposed, particularly if their files contain sensitive and/or upsetting diagnoses. 
Beyond that, patients who have their sensitive medical information ex-
posed can suffer harm in the employment and health insurance markets, in ad-
dition to reputational harm.477 Although people from all backgrounds can face 
these problems, it is a particular issue for those who rely on public benefits, 
such as those in nursing homes, foster care, and psychiatric institutions, be-
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cause regulations have increasingly facilitated the collection and public use of 
this particular data.478 
An increasing amount of health information is collected from individuals 
in public benefits programs such as Medicaid and Medicare. These patients 
tend to be poorer, sicker, older,479 and more vulnerable to breach of private 
health information damages—particularly those in captive settings. Vulnerable 
patients should not be subjected to potential extra violations of confidentiality, 
because their privacy and autonomy are already at risk. 
Finally, similar to informed consent, many patients are confused about the 
“basic ethical, legal, and practical limits on medical confidentiality.”480 In par-
ticular, the word “confidential” is not always understood, and many patients 
seem confused over which aspects of their medical information are protect-
ed.481 If this is true of a great many patients in general, how much truer will it 
be of those individuals who are vulnerable, captive subjects? 
There are simply too many problems with privacy and confidentiality to 
allow vulnerable, captive populations to participate in human research. Even if 
these individuals do agree to share their private medical records and infor-
mation, it is often without full understanding. Although sometimes the guardi-
ans or parents of these vulnerable, captive populations might consent to waiv-
ing medical confidentiality, the individual does not always agree (or was never 
asked). 
Finally, IRB committees, which are the primary regulatory bodies con-
cerned with patient privacy and confidentiality, were largely designed with the 
intent to “review trial design, risk-benefit ratios, and informed-consent docu-
ment” compliance, not to safeguard human privacy and autonomy.482 As I dis-
cuss in Part IV, we need much stronger controls and oversight over all human 
medical experimentation, but particularly over vulnerable populations.483 
C. Profits 
The profit motive intertwines with modern human medical experimenta-
tion. Pharmaceutical companies have tremendous financial incentive to test 
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new or patented drugs on a variety of captive subjects.484 Clinical research has 
transformed from an academic endeavor to a massive industry, where numer-
ous enterprises work in tandem with private doctors, hospitals, and university 
research centers.485 Due to the pressure from the drug companies to finish their 
studies as quickly as possible, doctors who are financially invested in clinical 
research sometimes persuade patients to take medications that are inappropri-
ate or even unsafe on an experimental basis.486 Patient rights can be lost in the 
hustle.487 
Physicians who conduct full-time commercial drug research routinely re-
port earning over $1 million in revenues every year, booking profits of 
$300,000.488 The development of psychiatric drugs is particularly big business. 
Although new antipsychotic drugs have revolutionized the lives of people liv-
ing with schizophrenia and other psychiatric illnesses, the clinical testing of 
these medications often results in a conflict between the pursuit of money and 
proper patient care.489 This tension between financial incentives and proper 
care has created “a landscape tarnished by the greed of some rogue investiga-
tors and repeated instances of patients being harmed.”490 
To take a recent example of the power of the drug and medical industry, it 
is instructive to look at the Best Pharmaceuticals for Children Act (BPCA).491 
The BPCA was passed in 2002 through an aggressive lobbying push that tar-
geted various pediatric research interests, including industry executives, gov-
ernment enterprises, and “industry supported organizations such as the Ameri-
can Academy of Pediatrics.”492 
Although safe and ethical clinical testing of pediatric medications is a 
laudable goal, there is frequently a conflict of interest when the drug maker 
sponsors the research. When industry funds the research, the medical journal 
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findings are often biased in favor of the sponsor’s interests.493 Research spon-
sored by nonprofit organizations do not exhibit such a bias.494 
The intimate ties doctors have with the drug industry span all corners of 
medical research. Recently, Dr. José Baselga, the chief medical officer of Me-
morial Sloan Kettering Cancer Center, resigned from the hospital and as an 
editor of a prestigious medical research journal.495 Baselga had failed to dis-
close millions of dollars he had received from drug and health care companies 
in his multiple publications detailing his cancer research findings.496 The doc-
tor consistently omitted his close financial ties to Swiss pharmaceutical com-
pany Roche and a variety of biotech startups in his medical journal publica-
tions. This in turn led to questions about his neutrality in presenting his re-
search findings.497 Further, Baselga served as a director on the boards of vari-
ous drug companies—roles that imposed fiduciary duties to the companies on 
him—while he simultaneously stewarded Sloan Kettering’s medical opera-
tions.498 
In addition, in 2017, Baselga extolled the virtues of two unsuccessful 
Roche-sponsored clinical trials, all the while failing to disclose his connection 
to Roche.499 Although Baselga ultimately resigned from Sloan-Kettering, he 
quickly gained employment at AstraZeneca, a sign of his extremely strong in-
dustry ties.500 
As ethicists have argued, failing to disclose such intimate financial com-
pany relationships, like Baselga’s, “can shape the way studies are designed and 
medications are prescribed to patients, allowing bias to influence medical prac-
tice.”501 The reporting requirements for disclosing such ties are very weak, 
however, and for the most part, leave the decision up to the submitting re-
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searcher.502 This failure to disclose industry funding can result in biased clini-
cal trial publications. These publications ultimately end up forming the basis of 
FDA approvals and clinical practice guidelines.503 
The boundaries between industry and academic research remain remarka-
bly porous, often to the patient’s disadvantage.504 A recent study found that 
67.2% of industry-funded research favored new treatments, compared to 
49.0% of nonprofit-funded research.505 The difference was even more dramatic 
for medical research using pharmaceutical drugs—65.5% of the industry-
sponsored studies showed the positive results of new treatment, compared to 
the 39.5% of noprofit-sponsored studies favoring the new treatment.506 In addi-
tion, industry-sponsored clinical studies may cherry-pick certain analyses of 
research data to better sell the benefits of certain drugs.507 
The pharmaceutical industry pays doctors a staggering amount of money 
for their “consulting” services. In a report studying the three years between 
2013 and 2016, ProPublica discovered that pharmaceutical companies such as 
Genentech, Pfizer, AstraZeneca, Allegan, and GlaxoSmithKline paid doctors 
millions of dollars to test, promote, and use their products.508 Given how pay-
ments or rewards given to doctors make them more likely to prescribe differ-
ently,509 the sheer amount of money given to doctors to test and use experi-
mental drugs raises serious concern. 
Unfortunately, there is little that health systems can do to require their 
doctors to behave ethically, outside of standard conflict-of-interest policies.510 
Although transparency about any ties to industry or drug companies is a goal, 
it often is neglected or brushed aside out of ignorance or laziness.511 Other 
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times, doctors do not even recognize that their professional neutrality has been 
skewed by their financial interests, and they are unaware that social psycholo-
gy—in particular, reciprocity norms—are unconsciously at work in their pre-
scribing and medical practice.512 
Further, industry-funded studies tend to demonstrate that a product is ef-
fective more often than independent studies, even when the researchers in-
volved fail to see any conflicts.513 Even when doctors do see conflicts, they 
often feel that simply disclosing them wipes the slate clean in terms of bias.514 
The existence of conflicts is now the status quo in medicine and research.515 
Moreover, clinical trials sponsored by the drug industry tend to give more fa-
vorable results to the specific drug tested.516 
This strong collaboration between medicine and industry distorts both 
medicine and clinical trials.517 This should be a familiar narrative at this point, 
as our history of human medical experimentation on the vulnerable is rife with 
troubling industry-science-medicine collaborations that primarily benefited 
commerce, not patients.518 For example, radiation treatments for cancer were 
primarily driven by the partnership between industry and medicine, where 
hospitals felt they needed to purchase increasingly powerful X-ray devices 
simply to appear modern in the eyes of patients and improve their finances, 
rather than improve the therapeutic success of their treatments.519 Similarly, as 
discussed in Part I, the history of testing radiation on captive subjects was not 
focused on helping patients; instead, the military-medical-industrial complex 
used these individuals for their own benefit.520 
Given that medical research can be biased in both the designs and the re-
sults of clinical research studies, there is a strong possibility that current clinical 
research is not only skewed in results, but also pushes new drugs or treatments 
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that may not be particularly effective. Given such bias, industry trials should not 
be allowed to enroll those who are already vulnerable in other aspects. 
IV. SAFEGUARDS AND SOLUTIONS 
A. Nomenclature: Disguising Human Medical Experimentation 
Naming is powerful. What we call a practice can greatly shape how it is 
perceived and accepted. Human medical experimentation is a prime example. 
As Dr. Carl Elliott has pointed out, what used to be known as medical experi-
ments on humans has now been recast as the far more anodyne “research stud-
ies” or “clinical trials.”521 Patients have become “research test subjects,” no 
longer human beings. The change in language reflects the effort to deflect con-
cerns about the treatment of research participants.522 
The research and medical industries are extremely motivated to use lan-
guage presenting their experiments as “safe, carefully regulated, and socially 
beneficial.”523 Indeed, the push to recast human medical experimentation from 
an ethically questionable to a socially beneficial practice has been very useful 
to those recruiting for pharmaceutical studies, because willing volunteers are 
always desired. The most recent change in phrasing, from “research subject” to 
“research participant,” casts the individual in an active, positive light—no 
longer passively being experimented upon, but instead choosing to participate 
in beneficial research.524 
The secrecy and obfuscating role of nomenclature in human medical ex-
perimentation goes further. As Harriet Washington contends, “the naming 
problem even impinges upon the acronyms by which clinical trials are known 
because they can undermine objectivity about the appropriateness of and ex-
pectations from the research.”525 Creating acronyms or nicknames such as 
CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial In-
vestigators) or HOPE (Heart Outcomes Prevention Evaluation) may give po-
tential subjects falsely high expectations for the results of the research trial.526 
These names give the research a positive connotation, making implicit promis-
es with little to back it up.527 
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In addition, research studies that use clever acronyms find it far easier to 
attract recruits, receive higher methodological study scores,528 and get more 
funding from major drug companies.529 For the average potential research sub-
ject, the use of acronyms to title research trials can border on the coercive, giv-
ing subconscious hope or encouragement to join the study.530 
Even calling research subjects “patients” can blur the realities of human 
medical experimentation, because there is no actual therapeutic relationship 
between the researcher and the subject, as there is between doctor and pa-
tient—what Dr. Katz called the “therapeutic illusion.”531 Nor do any of the typ-
ical rights of patients accrue in research scenarios.532 Research is not treatment, 
yet our language obscures and elides this crucial difference, resulting in “hu-
man subjects . . . being recruited to serve the interests of others.”533 
All of this opaque, misleading, or psychologically manipulative nomen-
clature makes it extremely difficult for the average, non-medically trained 
adult to properly understand and appreciate the full magnitude of human medi-
cal experimentation. How much more is this true for vulnerable, captive popu-
lations, who tend to have much more severe challenges comprehending the 
proposed contours of the human medical experiments? 
B. The Movement for Increased Participation by Captive Subjects 
Despite the many problems with using captive, vulnerable individuals for 
experimental medical research, there has been a renewed demand to expand 
federal and state limitations on human subject research. In particular, medical 
researchers, doctors, and the medical/pharmaceutical industry seek to widen 
their experimental access to prisoners and children. 
Some scientists and doctors believe that the current regulations banning 
most research in correctional facilities are too restrictive: first, because they 
unfairly limit prisoners’ ability to participate in medical trials; and second, they 
are an overreaction to the particular abuses in the 1960s and 1970s.534 They 
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argue that racial and ethnic minorities are already underrepresented in biomed-
ical research, and given their overrepresentation in correctional settings, ex-
cluding inmates from clinical research trials creates serious concerns for longi-
tudinal, participatory studies.535 
Proponents of expanding prison medical research contend that the inability 
to include inmates in surveys and following up with participants in correctional 
facilities may jeopardize the validity of scientific conclusions.536 Specifically, the 
loss of minority men from medical research due to incarceration may result in 
“biased, underpowered estimates” when studying health disparities.537 
Women, African-Americans, and Latinx are underrepresented in medical 
research, which adversely impacts the universality of the data.538 This un-
derrepresentation may also harm future patients as well as the scientific com-
munity.539 
Prisoners are currently not permitted to take part in experimental treat-
ments, which can provide desperately ill subjects a last chance at therapy.540 
Because many inmates are HIV positive, granting prisoners access to experi-
mental HIV research could be beneficial to the inmates and to society as a 
whole.541 Researchers in favor of loosening restrictions argue that the increas-
ing numbers of individuals in correctional facilities, who disproportionately 
suffer from HIV and hepatitis C, offer a useful possibility to control such dis-
eases if research access was increased.542 Similar benefits could accrue to in-
mates suffering from cancer, hepatitis, tuberculosis, and other diseases com-
mon in correctional facilities.543 
In response to these concerns, the Institute of Medicine (IOM) recom-
mended that the government loosen regulations on using prisoners for human 
medical research, particularly for testing pharmaceuticals.544 The IOM report 
concluded that riskier prison experiments should be permitted if they could 
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potentially benefit inmates, so long as there was an independent review to 
oversee the process.545 In doing so, the IOM’s framework for analyzing prison 
medical experimentation shifted from emphasizing protection and fairness to a 
more procedural mechanism focusing on inmate representation in research 
studies.546 
Concerns about underrepresentation and access to human research studies 
are genuine. That being said, using captive populations for medical experi-
ments is simply too risky. First, much of the push for widening the pool of po-
tential experimental volunteers to prisoners stems from industry.547 Biotech 
and pharmaceutical companies look at prisons and see a “deep pool of captive 
subjects with limited rights, housed in inherently coercive environments.”548 
Such a convenient assembly of research subjects is incredibly appealing, given 
the routine difficulties of finding participants for medical research.549 And us-
ing prisoners or other captive populations is particularly tempting for medical 
researchers, who gain the ability to easily control the subject’s diet, stimuli, 
environment, and routine interactions, thus ensuring fewer external influences 
interfering with the experiment. 
The call to expand the pool of experimental subjects to vulnerable or cap-
tive populations is not limited to prisoners. There is a similar argument to al-
low more human medical experimentation on children, despite the potential of 
their being “exploited as commodities for commercial ends.”550 
There are serious problems, however, with increasing child participation 
in medical research. Many of the children recruited to participate in such med-
ical research are economically disadvantaged minority children. In the face of 
their more limited access to quality health care, they and their families are 
more vulnerable to inducements to participate.551 These families, therefore, are 
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far more willing to enroll their children in medical research studies, something 
that is exploited by many major research centers.552 
Second, much of the desire to loosen restrictions on children and medical 
experimentations results from the dramatic rise of prescribing psychopharma-
ceuticals553 and behavioral drug treatments554 for children. Obtaining enough 
participants for pediatric clinical trials is difficult; pediatric patients comprise 
approximately twenty to twenty-five percent of the world’s population, and 
only a small subset of children suffers from the medical issues being stud-
ied.555 This means that there is a real shortage of subjects for pediatric re-
search. 
This shortage of available pediatric research subjects, however, makes the 
concomitant trend of medicating foster children with psychotropic drugs556 
very troubling. The vast majority of psychotropic drugs are FDA-approved 
only for adults, not children, leading to much off-label prescribing.557 Wide-
spread off-label prescribing results in a lack of clinically definitive data about 
the safety, dosage, and side effects of the drugs used on children.558 And the 
general lack of oversight for foster children’s health care means that frequently 
the most disadvantaged children participate in human medical experiments, 
particularly those testing psychotropic medication use in children. Foster chil-
dren provide a perfect captive, vulnerable population upon which to experi-
ment. 
Institutionalized patients suffering from mental illness are likewise 
viewed as grist for the clinical research mill. Certainly, mental illness is a con-
dition that deserves more dedicated research. Nevertheless, the relentless pres-
sure for rapid enrollment in clinical trials—particularly pharmaceutical trials 
for psychiatric drugs—has led to a focus on institutionalized patients for par-
ticipation.559 Psychiatric medications are one of the most frequently prescribed 
drugs in the world and in turn, make billions of dollars for their makers.560 As 
the Belmont Report noted, “the institutionalized may continually be sought as 
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research subjects, owing to their ready availability in settings where research is 
conducted.”561 
Complicating the situation, there are currently no specific legal protec-
tions protecting the mentally ill with impaired capacity.562 Although current 
U.S. regulations recognize the importance of providing ethical treatment of 
research subjects with mental disorders,563 there are no particular guidelines 
for IRBs and investigators.564 This makes using institutionalized, mentally ill 
patients in human medical experiments very tempting for the medical and 
pharmaceutical industries. 
The difficulty in obtaining enough patients for clinical trials—estimated 
to take up to thirty percent of clinical research study time565—is an insufficient 
reason to allow vulnerable, captive subjects to participate in medical experi-
mentation. The patient recruitment problem costs pharmaceutical companies 
millions, and it slows down the pace of drug development.566 Accordingly, this 
recent desire to increase the use of captive subjects for clinical research trials is 
questionable. As an industry-sponsored news site observed, “the 2.3 [million]-
strong U.S. prison population remains an untapped resource for patients who 
are perfect for clinical trials, including racial minorities, women, as well as 
people with mental illness and communicable diseases such as HIV/AIDS, 
hepatitis C, and tuberculosis.”567 This call for greater prisoner participation in 
research studies from the medical industry is hardly altruistic. 
Although local or institutional review boards are supposed to provide 
strict oversight for any research performed on vulnerable populations, their 
monitoring is often haphazard and half-hearted. Review board members are 
required to follow the ethical principles from the 1947 Nuremberg Code and 
the 1964 Helsinki Declaration, but in reality, these boards are frequently under-
                                                                                                                           
 561 NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMED. & BEHAVIORAL RE-
SEARCH, U.S. DEP’T OF HEALTH, EDUC., & WELFARE, THE BELMONT REPORT 10 (1979), https://
www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL.pdf [https://perma.cc/HF2V-
GPLV]. 
 562 See NAT’L BIOETHICS ADVISORY COMM., An Overview of the Issues, in RESEARCH INVOLV-
ING PERSONS WITH MENTAL DISORDERS THAT MAY AFFECT DECISIONMAKING CAPACITY (1998), 
https://bioethicsarchive.georgetown.edu/nbac/capacity/Overview.htm [https://perma.cc/9EZA-V5XH]. 
 563 See 45 C.F.R. § 46.111(b) (2018) (requiring consideration of additional protections where 
“some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as chil-
dren, prisoners, individuals with impaired decision-making capacity, or economically or educationally 
disadvantaged persons”); NAT’L BIOETHICS ADVISORY COMM., supra note 562. 
 564 See NAT’L BIOETHICS ADVISORY COMM., supra note 562. 
 565 See Kirsty Barnes, Prisoners May Be Used to Fill Clinical Trial Patient Shortage, OUTSOURC-
ING-PHARMA (July 19, 2008), https://www.outsourcing-pharma.com/Article/2006/08/17/Prisoners-
may-be-used-to-fill-clinical-trial-patient-shortage [https://perma.cc/36LV-HJS5]. 
 566 See id. 
 567 See id. 
62 Boston College Law Review [Vol. 61:1 
trained and overworked.568 Further, many of the academic research centers 
running these clinical research studies are funded partially by commercial en-
terprises, including the very pharmaceutical companies manufacturing the 
drugs being tested, as well as other interested parties.569 Our current oversight 
system is undermined by a systemic and continual conflict of interest.570 
To make matters worse, the Office for Protection from Research Risks 
(OPRR), which oversees all the local review boards, is itself part of the NIH, 
which has both conducted and funded much of the human medical research 
performed on captive subjects.571 If and when the OPRR discovers an institu-
tional failure to follow the rules, it has no ability to fine or discipline. Instead, 
the OPRR can merely request changes in order for the institution to comply 
with OPRR’s primary tool, the ‘‘assurance’’ document, which is the institu-
tion’s pledge to follow federal research regulations.572 
Despite the variety of reasons to continue restricting medical experimen-
tation on prisoners, the premise of unfettered research access to captive human 
subjects persists. In 2018, a group of medical researchers, looking to conduct a 
long-term, wide-ranging study on how salt intake affects heart disease, selected 
inmates as the best set of captive subjects, proposing to use a randomized con-
trolled trial with varying salt intakes for several years.573 The researchers re-
jected various other sets of captive populations, including nursing home inhab-
itants (because it was too difficult to alter their diets), and military recruits (be-
cause they were generally too young to be able to see the results on heart dis-
ease in a timely fashion).574 The salt intake plan would begin with a pilot pro-
ject involving prisoners aged fifty-five and over, followed by a five-year trial 
involving 10,000 to 20,000 older prisoners.575 
There are myriad problems with this proposal. Although generally it may 
be useful to know the optimal amount of salt to ingest, “[p]rivileging the po-
tential public health benefits of a study over protections for vulnerable persons, 
even when risks are judged as minimal, is a gateway to future decisions priori-
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tizing majority health over individual rights.”576 Additionally, prisoners demo-
graphically are overwhelmingly male and minority, with higher rates of HIV, 
tuberculosis, and hepatitis C, a fact that does not make them like an average 
test subject.577 
Proponents of reinstating prisoner research have argued that this study 
will help the inmates themselves, in that it will provide them the extra health 
benefits as well as a psychological benefit of having “agency and representa-
tion.”578 These arguments are both flawed. The fact that inmates’ health might 
benefit from participating in medical experiments simply highlights the very 
low level of health care that they normally receive in correctional facilities.579 
Performing human medical experiments on inmates is not the proper solution 
to poor prison health care. 
As for the argument that inmates may gain psychological utility from the 
agency and representation of participating in a medical experiment, this, too, is 
dubious. First, the inmates may be coerced to participate because the prison 
may obtain money or other incentives for their participation in the research. 
Also, it is unclear how many prisoners would wish to participate in a possibly 
long or arduous study just to improve the percentage of minority participants 
in scientific research.580 
Finally, the very limited ability of inmates to obtain any legal remedy if a 
medical experiment goes wrong or is performed unethically should give us great 
pause. In general, prisoners have extremely restricted legal rights due to the 
qualified immunity of prison officials.581 As we have seen from past lawsuits of 
prisoners severely injured in medical experiments, such as the skin experiments 
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at Holmesburg Prison, the ability of inmates to obtain any meaningful remedy or 
recompense after abusive or unethical behavior is very limited.582 
In short, inmates, foster children, the institutionalized, and nursing home 
patients should not be seen as human medical experiment material simply be-
cause they “represent a sample of convenience.”583 At minimum, we should 
protect our most vulnerable, captive individuals by maintaining the current 
restrictions. 
C. New Guidelines for the 21st Century 
“[R]evisiting guidelines does not mean eliminating restrictions.”584 
So how can we best encourage clinical research and the testing of new 
medications without abuse or exploitation? Below I sketch out a few safe-
guards that would continue to protect our most vulnerable populations from 
exploitation and abuse, while still allowing medical research to continue with 
other, less fragile groups. 
1. Maintain Current Restrictions on Experimental Prison Research 
There are important reasons why federal restrictions on human medical 
experiments in correctional facilities are still in place, notwithstanding the pe-
riodic attempts to loosen them made by various interest groups. Despite the 
admitted need for better minority male representation in clinical research, us-
ing inmates as convenient laboratory specimens is not a solution. Given the 
problems with duress, inducement, lack of privacy, and compromised informed 
consent, as discussed above, there is no way to properly oversee medical ex-
periments or make up for the coercive nature of incarceration. Accordingly, 
any attempt to recruit the individuals currently imprisoned by the criminal jus-
tice system for clinical trials should be halted. 
2. Tightly Restrict Research on Foster Children, the Institutionalized, and 
Long-Term Care Residents 
These three vulnerable, captive populations—foster children, the mentally 
compromised, and long-term care patients—should have very limited oppor-
tunity to participate in clinical research trials. All three groups frequently must 
rely on other individuals to make decisions for them, and often family mem-
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bers or guardians are too uninformed, overworked, or confused to give proper 
informed consent. 
Foster children, who already suffer from the disruption of family removal 
and, too frequently, a revolving array of doctors, caseworkers, and foster par-
ents, should not be allowed to enroll in any clinical research trials unless their 
health depends on it. In addition, all foster children should have an extra layer 
of oversight when long-term medications or treatments are prescribed.585 
Long-term care residents should also have substantial restrictions on clin-
ical trial participation, particularly because they often possess limited cognitive 
abilities. Complicating matters, their proxies or guardians do not always real-
ize the full implications of participating in medical research and the side ef-
fects or negative aspects of the experiments. 
Obtaining consent to perform medical research at long-term care facilities 
frequently requires two levels of consent: first, from the facility managers and 
staff, and then, if possible, from the residents or their proxies.586 Although re-
sponsible researchers are supposed to ensure the patient’s competency to con-
sent, the onus truly lies on the individual clinician.587 This discretion can lead 
to abuse. The ethical recruiting, retaining, and obtaining of informed consent 
from long-term residents is often quite difficult,588 particularly when residents 
have dementia or other comprehension problems. In addition, many residents 
are unwilling to participate, as they do not trust the researchers’ motives or 
dislike their daily routine’s interruption.589 As such, there is a danger of coer-
cion to participate. 
Further, most long-term care homes do not have an internal IRB or other 
oversight body and require an external board for supervision,590 a fact that only 
exacerbates the problem of insufficient oversight and control of medical re-
search. Given our long and shameful history of conducting medical experi-
ments on the aged and terminally ill,591 we should bar any clinical research on 
those long-term care residents unless the object is entirely safe and therapeutic. 
Similar restrictions on medical research should apply to those individuals 
who are civilly committed, particularly for psychiatric reasons. Like prisoners, 
the involuntarily committed are captive populations, “isolated and dependent 
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on institutional authorities,” and thus present a high barrier for obtaining vol-
untary informed consent.592 Worse, the Common Rule, which covers much 
federally funded medical research, excludes the civilly committed by defining 
prisoners very narrowly, recognizing only those incarcerated within the crimi-
nal justice system.593 Any set of meaningful restrictions on medical research 
must include this particular group of captive individuals. 
3. Technology to the Rescue 
Can future technological innovations protect captive, vulnerable popula-
tions while encouraging future medical research? 
Given the fast pace of technological change, it is entirely possible that ar-
tificial cells and synthetic cadavers could replace the use of humans in medical 
experiments if used creatively. For example, synthetic cadavers are already 
being used in medical device studies, obviating the use of human cadavers.594 
If synthetic humans can be used to replace human cadavers for simulation and 
medical device studies, there is no reason that they cannot be developed in the 
future to replace humans entirely in clinical research trials. In fact, one syn-
thetic human company, SynDaver, notes that this prototype is in development 
already: “a synthetic autonomic nervous system (real-time human physiology 
computer) for the SynDaver Synthetic Human platform—essentially a full 
body that can move, breathe and bleed autonomously.”595 
Similarly, a Swiss company, Empa, has created a synthetic skin that can 
simulate the characteristics of human skin, reproducing “its frictional behav-
iour against textiles in dry and hydrated conditions.”596 The plan is to use this 
synthetic skin in place of clinical trials with human skin to avoid any risk of 
harm.597 Synthetic bone is also in development, and hopes are that this bone 
substitute can be used in the human body alongside natural bone.598 Obviously, 
this kind of synthetic bone could also be used for clinical research and testing, 
thus sparing humans. This kind of biotechnological development has the po-
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tential to replace the human element of human subject research, eliminating 
the risk and coercion inherent in much clinical research. 
The ability to grow replacement organs and spare parts outside the body 
also shows potential to replace some forms of human subject research.599 If 
synthetic organs can be created, then there will be a whole world of possibility 
opened to those doctors and researchers who want to test various procedures, 
medicines, and devices on human body parts. The expanding world of bio-
material may someday negate the need to use human bodies at all. 
Until that day comes, however, we must continue to protect the poor, the 
imprisoned, the developmentally disabled, the young, the mentally ill, and the 
elderly from medical experimentation that can be highly coercive and under-
regulated. Although regenerative engineering gives us hope for the future, it is 
important to protect the vulnerable of today, particularly those in captivity. 
CONCLUSION 
It is all too easy for us to decry the barbarity of the past with human med-
ical research, whether we reach back to former centuries or focus on more re-
cent experiments, such as the Tuskegee Study or the Atomic Energy Commis-
sion’s radiation experiments. In many important ways, however, our use of 
captive, vulnerable populations in today’s medical experimentation continues 
down the same path. Although the underlying motivations may be different, we 
continue to improperly experiment on the incarcerated, the institutionalized, 
wards of the state, and the extreme poor, far too often in furtherance of indus-
try profit. Current federal guidelines and legislation have failed to stem the tide 
of unethical clinical research. Until the promise of biotechnology can remove 
humans entirely from clinical medical research, we must restrict such experi-
mentation to those who freely and knowingly consent. 
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